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7ABSTRACT 
Traditional cardiovascular risk factors in midlife are known to associate with memory 
illness in later life. In late-life, however, this association is less clear. Recognition 
of new modifi able cardiovascular risk factors with prognostic capacity on memory 
illness are needed in the older population. In recent years, the association between 
natriuretic peptides, biomarkers of direct cardiovascular stress, and cognitive decline 
has been addressed within a few studies. Severe cognitive decline and depressive 
symptoms have been linked to increased mortality amongst the elderly. The impact 
of mild cognitive decline on mortality has been less clear. Increased cardiovascular 
morbidity, mood disorders and memory illnesses are conditions that may overlap in 
older people. The aim of this study was to investigate the impact of B-type natriuretic 
peptide (BNP) – a marker of cardiovascular stress – on mortality, together with 
the Mini Mental State Examination Score (MMSE) and depressive symptoms 
in combination with established cardiovascular risk factors in an older general 
population. Another aim of this study was to investigate how the prognostic capacity 
of BNP on memory illness varies with aging, and to examine the relationship between 
BNP and the severity of memory illness. 
This study was based on the Kuopio 75+ health study, a prospective age-stratifi ed 
cohort study with 601 individuals aged 75 years or over. The participants were 
examined at the entry of the study and during a fi ve-year follow-up visit. Clinical 
examination including assessment of cognitive function and laboratory count 
including BNP were performed. Mortality data were obtained from Statistics Finland. 
BNP was a strong predictor of all-cause and cardiovascular mortality when 
examined together with MMSE score or depressive symptoms. An MMSE score 
of 18–23 was a predictor of total rather than cardiovascular mortality. Depressive 
symptoms had no signifi cant independent predictive value on total or cardiovascular 
mortality. BNP had prognostic capacity on memory illness in the 75–78 years age-
group, but not in older age-groups. BNP was also associated with mild memory 
illness, but this association was lost in the more severe forms of memory illness.  
In conclusion, BNP showed good performance as a predictor of all-cause and 
cardiovascular mortality when tested together with MMSE score or depressive 
symptoms in combination with established cardiovascular risk factors in the elderly 
population. The relationship between BNP and memory illness varies by age and 
progression of disorder, as the previously found link between BNP and memory 
illness is present only in the population aged under 79 years and in mild stages of 
disorder. More information is needed especially for recognizing prognostic tools for 
the identifi cation of older individuals at elevated risk of mortality and developing 
a memory illness.  
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1 INTRODUCTION 
The prevalence of moderate to severe memory illness in people aged 70 years or 
over has been estimated to be 9.5%–18% (Suthers et al. 2003, Corrada et al. 2010), 
and markedly higher prevalences of memory illness are reported in populations 
over 80 or 90 years of age (Corrada et al. 2010, Jorm and Jolley 1998). As the 
elderly population increases, the number of people with Alzheimer’s disease has 
been estimated to rise threefold by 2050 from the level of 2000 in the United States 
(Hebert et al. 2003). The total number of people affected by memory illness has 
been estimated to increase up to 81 million by 2040 (Ferri et al. 2005). In Finland, 
the number of people affected by moderate or severe memory illnesses has been 
estimated to increase 1.5 fold by 2020 from the level of 2006. (Viramo and Frey 
2006) 
In addition to human suffering, memory illnesses cause an enormous economic 
burden to society. In 2010, the total costs of memory illnesses the United Kingdom 
were calculated to be GBP 23 billion per year – more than the costs of cancer (GBP 
12 billion per year) and heart disease (GBP 8 billion per year) combined. So far, 
the treatment of memory illnesses has been more or less symptomatic. Due to the 
absence of curative treatment for diseases causing cognitive impairment, prevention 
targeted on modifi able risk factors is needed.  
Natriuretic peptides are hormones secreted from the heart chambers in response 
to increased mechanical load and wall stretch in several cardiovascular conditions 
(Vuolteenaho et al. 2005, Daniels and Maisel 2007). In clinical practice, natriuretic 
peptides have established their use in the diagnostics and follow-up of heart failure. 
In earlier studies, natriuretic peptides have been linked to cognitive decline (Buerger 
et al. 2009, Gunstad et al. 2006, Daniels et al. 2011). Natriuretic peptides have also 
been indicated as a predictor of mortality in various high-risk populations, including 
older people (Kistorp et al. 2005, Wallen et al. 1997, Daniels et al. 2008). 
Severe cognitive decline increases mortality amongst the elderly (Kelman et 
al. 1994, Larson et al. 2004), but the impact of mild cognitive impairment on 
mortality has been less clear (Fried et al. 1998, Stump et al. 2001, Nguyen et al. 2003, 
Strandberg et al. 2009).  Depressive symptoms have been linked to poor prognosis 
(Baldwin 2000, Saz and Dewey 2001) and increased cardiovascular morbidity and 
mortality (Junger et al. 2005, Jiang et al. 2007, Kato et al. 2009, Rumsfeld et al. 
2005). Cardiovascular morbidity increases with aging. In the elderly, cardiovascular 
morbidity, mood and declining cognition may form a junction where these conditions 
overlap, together affecting the quality of life and increasing mortality. The impact of 
haemodynamic load on this junction of multi-morbidity introduces an interesting 
14
1 Introduction 
unsolved aspect to the efforts made to fi nd preventive measures for cognitive decline 
and mortality in the elderly. 
15
2 REVIEW OF THE LITERATURE 
2.1  TRADITIONAL CARDIOVASCULAR RISK FACTORS AND   
 COGNITION 
2.1.1  STROKE AND COGNITION 
The most important cerebrovascular pathology contributing to cognitive decline 
is a cerebral infarct (Gorelick et al. 2011).  A history of stroke doubles the risk 
of developing a memory illness in the older population (Savva et al. 2010). In a 
Finnish study (n=486), cognitive decline and dementia were frequent in the cohort 
of ischemic stroke patients three months after stroke (Pohjasvaara et al. 1997). 
In the Nun Study (n=102), individuals with brain infarctions showed increased 
prevalence of memory illness, and fewer neuropathologic lesions of Alzheimer’s 
disease (AD) were needed to result in memory illness in participants with lacunar 
infarcts in comparison to those without infarcts (Snowdon et al. 1997). 
Hypertension is associated with changes in the structure of cerebral blood vessels 
(Iadecola et al. 2009), and high blood pressure has been recognised as a major 
risk factor of cardiovascular disease and stroke (Lawes et al. 2004, Kearney et al. 
2005, Goldstein et al. 2011). Cardiovascular risk factors in midlife are associated 
with the risk of both stroke and developing memory illness late in life.  In Table 1, 
some studies are presented investigating the association between cardiovascular risk 
factors and memory illness. One large study (4153 men and 1657 women) assessed 
the association between the risk of stroke in mid-life and cognitive decline using the 
Framingham Stroke Risk Profi le (FSRP). The FSRP incorporates age, sex, systolic 
blood pressure, diabetes mellitus, smoking, prior cardiovascular disease, atrial 
fi brillation, left ventricular hypertrophy and the use of antihypertensive medication. 
The main fi nding in this study was that an elevated risk of stroke in mid-life predicted 
worsening cognition over a period of 10 years of follow-up (Kaffashian et al. 2013). 
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Table 1. Studies investigating the association between traditional cardiovascular risk factors and memory 
illnesses 
 N Age Outcome 
Blood 
pressure    
Kivipelto 
2001 1449 
mean age 50 at 
entry, follow-up 21 
years 
High systolic blood pressure in mid-life 
increased risk of AD in late-life (OR 2.8, 95% 
CI 1.1-7.2) 
Whitmer 
2005 8845 
40–44 at entry, 
average follow-up 
27 years 
Hypertension in mid-life increased the risk 
of developing dementia in later life (HR 1.24, 
95% CI 1.04 to 1.48) 
Tsivgoulis 
2009 19836 45 years 
Higher diastolic blood pressure was cross-
sectionally and independently associated 
with impaired cognitive status. An increment 
of 10 mm Hg in diastolic blood pressure was 
associated with 7% (95% CI 1%–14%) higher 
odds of cognitive impairment. 
Reijmer 2012 380 
mean age 57.7 years 
at baseline, mean 
follow-up time 15.3 
years 
High blood pressure in mid-life was 
associated with cognitive dysfunction in late-
life, but this association gradually attenuated 
with increasing age. 
Verghese 
2003 488 
>75 years, median 
follow-up 6.7 years 
Low diastolic pressure was associated with 
higher risk of dementia   (HR 2.19, 95% CI 
1.27 to 3.77) 
Qiu 2003  1270 75–101 years, follow-up 6 years 
Subjects with very high systolic pressure 
(>180 vs 141–180 mm Hg) had an adjusted 
relative risk of 1.6 (95% CI, 1.1–2.2) for 
dementia.  Extremely low diastolic pressure 
(</=65 vs 66–90 mm Hg) had an adjusted 
relative risk of 1.5 (95% CI, 1.0–2.1; P =.03) for 
dementia. 
Yap 2008 2321 
mean age 65.5 
years, 1–2 years of 
follow-up 
Orthostatic hypotension in combination with 
hypotension increased the risk of cognitive 
impairment (OR 4.1, 95% CI 1.11–15.1) 
Diabetes    
Whitmer 
2009 16667 
mean age 65 years, 
follow-up time 27 
years 
Amongst older patients with type 2 
diabetes, a history of severe hypoglycemic 
episodes was associated with a greater risk 
of dementia  (HR 1.94 for patients with 3 
or more hypoglycemic episodes, 95% CI, 
1.42–2.64) 
Cukierman 
2005 8656 
55 years, follow-up 
time 2–18 years 
A systematic review comprising 25 articles 
found that diabetes increased the odds of 
future dementia 1.6-fold (95% CI 1.4–1.8). 
Cholesterol    
Kivipelto 
2001 1449 
mean age 50 at 
entry, follow-up 21 
years 
High serum cholesterol concentration in 
midlife increase the risk of AD in later life 
(OR 2.2, 95% CI 1.0–4.7) 
Whitmer 
2005 8845 
40–44 at entry, 
follow-up 30 years 
High cholesterol in mid-life was associated 
with the risk of dementia (HR 1.42, 95% CI 
1.22 to 1.66) 
Solomon 
2007 1449 
mean age at midlife 
50.4 years average 
follow-up 21 years 
High cholesterol in mid-life was a risk factor 
for developing dementia (OR 1.8, 95% CI 
1.1–3.0). A moderate decrease in cholesterol 
from mid-life to late life was associated 
with cognitive impairment (OR 3.5, 95% CI 
1.5–8.0). 
Mielke 2010 1462 
women aged 38-
60 years at entry, 
follow-up 32 years 
Higher cholesterol level at baseline was not 
associated with an increased risk of AD 
(highest vs lowest quartile: HR 2.82, 95%CI 
0.94–8.43). Decrease in cholesterol over  the 
follow-up was associated with an increased 
risk of dementia (HR 2.35, 95% CI 1.22–4.58). 
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Smoking    
Peters 2008 
A meta-
analysis 
including 
23 studies. 
The size of 
population 
ranged 
from less 
than 1000 
to over 
34,000 
in studies 
included 
not available of all 
the studies included 
in the meta-analysis 
Summary ratios for current smokers versus 
never- or non-smokers were 1.59 (95% CI 
1.15–2.20) for AD, 1.35 (95% CI 0.90–2.02) for 
VaD, 1.16 (95% CI 0.90–1.50) for unspeciﬁ ed 
memory illness, and 1.20 (95% CI 0.90–1.59) 
for cognitive decline 
AD, Alzheimer´s disease; OR, odds ratio; CI, conﬁ dence interval; HR, hazards ratio; mmHg, millimeter 
of mercury; Vad, vascular dementia 
2.1.2 BLOOD PRESSURE AND COGNITION 
The association of blood pressure and cognition has been investigated in several 
studies, and the evidence links high blood pressure in midlife to cognitive 
dysfunction in later life (Kerola et al. 2011, Kloppenborg et al. 2008, Kivipelto et 
al. 2001, Whitmer et al. 2005). In the Framingham Heart Study (n=1814, aged 
40–69 years), midlife hypertension was associated with poorer performance in 
executive function and visuomotor skills (Wolf et al. 2007). In the Reasons for 
Geographic and Racial Differences in Stroke (REGARDS) Study (n=19836; aged ≥45 
years), high diastolic blood pressure was independently associated with impaired 
cognitive status (Tsivgoulis et al. 2009). In the Hoorn Study (n=380; mean age 
57.7 at baseline), high systolic blood pressure was associated with late-life cognitive 
dysfunction (Reijmer et al. 2012).  
In the older population, the results concerning the association between blood 
pressure and cognitive dysfunction are more diverse.  Amongst older populations, 
some studies link low diastolic blood pressure in particular with cognitive decline. 
One prospective study found that in older people (n=339; aged 85 years or over), 
a history of hypertension was linked with a lower probability of dementing illness 
(Rastas et al. 2010). The Helsinki Aging Study found that declining blood pressure 
was associated with future cognitive decline (Kähönen-Väre et al. 2004). In the 
Bronx Aging Study amongst elderly individuals aged over 75 (n=406), persistently 
low blood pressure increased the risk of developing a memory illness during follow-
up (HR 2.19; 95% CI 1.27–3.77) (Verghese et al. 2003). Similar fi ndings were made 
in a longitudinal study where 422 elderly persons aged 81 or more were followed 
up to three years and low diastolic blood pressure was found to predict the risk of 
dementia. Blood pressure exhibited a decline over approximately 3 years before the 
cognitive decline became clinically evident (Qiu et al. 2009). In a Chinese study 
among an elderly population (n=2321), co-existing orthostatic hypotension in 
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hypotensive participants increased the risk of cognitive impairment (OR = 4.1; 95% 
CI 1.11–15.1), but orthostatic hypotension alone was not associated with cognitive 
decline (Yap et al. 2008).  
There are also contradictory fi ndings on the relationship between blood pressure 
and cognitive decline in the elderly, as some studies show an association between 
high blood pressure and cognitive dysfunction amongst older populations. In the 
The Hypertension in the Very Elderly Trial (HYVET; n= 3763, aged 80 or over), 
high blood pressure was associated with cognitive decline (Peters et al. 2009). 
In the COGNIPRES study (n=1597), the prevalence of cognitive impairment was 
investigated in hypertensive individuals over 60 years of age. The fi nding was that 
the prevalence of cognitive impairment amongst hypertensive patients aged over 
60 years was 12.3% and a good control of blood pressure was associated with 
better cognitive performance (Vinyoles et al. 2008).  In a longitudinal study with a 
community-based, dementia-free cohort (n = 1270) aged 75 to 101 years and six years 
of follow-up, low diastolic and high systolic pressure were associated with increased 
risk of dementia disorder (Qiu et al. 2003). In the Baltimore Longitudinal Study of 
Aging  (n=847), the association between blood pressure and poorer performance 
in neuropsychological tests resembled a U-shaped curve linking both low and high 
diastolic blood pressure to cognitive dysfunction (Waldstein et al. 2005). 
It is not clear whether blood pressure changes in late life are a cause or a 
consequence of dementia disorder; or whether there is any causal link between 
these two entities. Several pathological mechanisms have been suggested to link 
abnormal blood pressure to cognitive decline (Novak and Hajjar 2010, Novak 2012). 
High blood pressure promotes atherosclerosis in cerebral arteries via vascular 
remodelling of small and large vessels (Droste et al. 2003). Hypertension in midlife 
may lead to endothelial dysfunction, an impairment of autoregulation, infl ammation 
as well as microvascular and macrovascular disease, which are all associated with 
diseases causing cognitive decline by disrupting the cerebral blood supply. Cerebral 
microvascular disease has been linked with regional hypoperfusion and loss of brain 
volume (Novak 2012). As hypertension is a risk factor of cerebrovascular disease, 
elderly people with silent brain infarcts have an increased risk of dementia (Vermeer 
et al. 2003). Higher pulse pressure associated with dementia in the elderly may 
be due to severe atherosclerosis and arterial stiffness (Nagai et al. 2010). A French 
study showed a relationship between arterial stiffness and both AD and vascular 
dementia (VaD) (Hanon et al. 2005a).  
Chronic hypertension induces the remodelling of cerebral arteries and leads to a 
reduction of their lumen (Iadecola and Davisson 2008). Hypertension also causes 
damage to the blood-brain barrier, exposing neurons to cytotoxic molecules and 
leading to neuronal loss (Pires et al. 2013). Disturbances in cerebral autoregulation 
amongst patients with hypertension are associated with white matter lesions 
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(Matsushita et al. 1994). MRI-determined white matter hyperintensities associated 
with global and regional brain atrophy (Appelman et al. 2009) are connected to 
higher blood pressure. In a prospective population study, the long-term effect of 
high blood pressure was examined. It was found that the presence of white matter 
lesions was also associated with an increase in diastolic pressure (>10 mm Hg), 
systolic pressure (>40 mm Hg), pulse pressure (>24 mm Hg) and mean arterial 
pressure (>6 mm Hg) during 24-year follow-up (Guo et al. 2009). White matter 
hyperintensities are associated with cognitive dysfunction and with a progression 
of cognitive defi cits (de Groot et al. 2001, O’Brien et al. 2003).  
 Cerebromicrovascular disease associated with white matter lesions is also 
linked with neuronal degeneration and accelerates the decline in cerebral blood 
fl ow with age (Novak and Hajjar 2010). One study with a limited number of 
subjects showed that, in older hypertensive people, cerebral blood fl ow is reduced 
in specifi c areas of the brain. These areas affected by hypertension and resulting in 
functional vulnerability included the prefrontal cortex, anterior cingulate gyrus and 
the hippocampus – regions implicated in relation to memory, executive function 
and attention (Beason-Held et al. 2007). 
Low blood pressure and orthostatic blood pressure may indicate a dysfunction 
of the autonomic nervous system connected with degenerative diseases that cause 
impaired cognition, such as AD dementia with Lewy bodies (DLB) and Parkinson’s 
disease, as a dysfunction of the autonomic nervous system has been linked to these 
morbidities (Allan et al. 2007, Idiaquez and Roman 2011). It has also been suggested, 
however, that a decline in blood pressure could precede the onset of dementia by 
three years (Qiu et al. 2009). In a follow-up study amongst elderly non-demented 
people, those who had both higher systolic and higher diastolic blood pressure at the 
age of 70 were at a higher risk of developing dementia. A decline in blood pressure 
levels was also observed years before dementia onset (Skoog et al. 1996). Studies 
have shown that normal aging reduces cerebral blood fl ow by 20% by the age of 60 
as compared to the age of 20 years (de la Torre 2012). A loss of perfusion regulation 
linked to hypotension may have an impact on the cognitive network when blood 
pressure drops below the autoregulation range (Novak and Hajjar 2010). Orthostatic 
hypotension may have an additive impact on hypotension-related loss of suffi cient 
perfusion of the brain, and can thus worsen cognitive decline (Novak 2012). 
 As the evidence shows an association between hypertension and cognitive 
decline, expectations have been laid on antihypertensive treatment as a protection 
of cognition. So far, the studies addressing this major issue have yielded confl icting 
results. As several studies have investigated the potential protective effect of 
antihypertensive treatment on cognition, only the major studies are presented here. 
In the Syst Eur trial, treating hypertension in subjects aged 60 years or over (n=2418, 
mean age 70 years) reduced the incidence of dementia by 50% from 7.7 to 3.8 cases 
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per 1,000 patient-years (Forette et al. 1998). The extended follow-up of four years 
in the same trial (n=2902, mean age 68 years) demonstrated that treating the 
hypertension of 1,000 patients for 5 years can prevent 20 cases of dementia (Forette 
et al. 2002). In the Heart Outcomes Prevention Evaluation (HOPE) trial (n=9297, 
mean age 66 years), treatment with rampiril, an angiotensin-converting enzyme 
(ACE) inhibitor, was associated with a 41% reduction in cognitive-decline-related to 
stroke over 4.5 years of follow-up. (Bosch et al. 2005). The Systolic Hypertension in 
the Elderly Program (SHEP) study, with a mean follow-up time of fi ve years (n= 4736, 
mean age 74 years), showed no cognitive benefi t when hypertension was treated with 
chlorthalidone and also with atenolol(Applegate et al. 1994). In the Hypertension 
in the Very Elderly trial, consisting of cognitive function assessment (HYVET-
COG) amongst very old people (n=3336, mean age 84 years), antihypertensive 
treatment with indapamide or perindopril in elderly patients did not statistically 
reduce incidence of dementia (Peters et al. 2008). In the ONgoing Telmisartan Alone 
and in combination with Ramipril Global Endpoint Trial (ONTARGET), and in a 
parallel sub-study entitled the Telmisartan Randomized AssessmeNt Study in ACE 
iNtolerant subjects with cardiovascular Disease (TRANSCEND), treatment with 
the ACE inhibitor ramipril, the AT-2-blocker telmisartan or a combination of these 
two medications produced no clear benefi t in cognitive measures amongst patients 
aged 55 years and older suffering from an established atherosclerotic cardiovascular 
disease or diabetes with end-organ damage (Anderson et al. 2011).  
Based on these confl icting results, the American Heart Association and American 
Stroke Association have published a statement concerning vascular contributions 
to cognitive decline. They recommend lowering blood pressure in stroke patients 
as well as middle-aged and young-elderly hypertensive patients. In hypertensive 
patients aged 80 or over, lowering blood pressure for the prevention of memory 
illness is not well-established (Gorelick et al. 2011). Explanations can be addressed 
regarding these confl icting results. The follow-up time in the studies has been 
relatively short, considering that the development of a memory illness is usually a 
slow process that takes place over a series of years. Furthermore, the studies have 
not included cognitive decline as a primary end-point – i.e. preventing cognitive 
decline has not played a major role in the investigations.  
2.1.3 DIABETES AND COGNITIVE FUNCTION 
Epidemiological studies show that diabetes mellitus increases the risk of developing 
a memory illness (Strachan et al. 2011). In a systematic review of the prospective 
data relating diabetes status to changes in cognitive function over time, it was found 
that the odds of future dementia increased 1.6-fold (95% CI 1.4–1.8) in subjects with 
diabetes as compared to those without (Cukierman et al. 2005). Another review 
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article gathered together evidence from population-based studies and concluded that 
diabetes mellitus increased the risk of undefi ned memory illness in seven out of 10 
studies. A higher risk of AD was also reported in eight out of 13 studies and that of 
VaD in six out of nine studies (Biessels et al. 2006). In a large longitudinal cohort 
study (n=16667, mean age 65 years), hypoglycaemia was assessed as a potential 
risk factor for memory illness in older patients with type 2 diabetes. The main 
fi nding was that a history of severe hypoglycaemic episodes were associated with a 
greater risk of memory illness (Whitmer et al. 2009). In the Diabetes Control and 
Complications trial, younger subjects with type 1 diabetes (n=1144, mean age at entry 
27) were followed up for up to 18 years. Higher HbA1C values were associated with 
a moderate decline in motor speed and psychomotor effi ciency, but no evidence 
of substantial long-term decline in cognitive function was found, despite relatively 
high rates of hypoglycaemic episodes (Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications Study Research Group 
et al. 2007).  
The effect of intensive treatment of diabetes on cognition has been studied, 
but large intervention trials have not shown promising results. However, despite 
the results gained from the studies, it has been proposed that cognitive function 
should be included as a standard end point in therapeutic intervention trials on 
individuals with type 2 diabetes mellitus (Strachan et al. 2011). In the Action to 
Control Cardiovascular Risk in Diabetes – Memory in Diabetes (ACCORD-MIND) 
trial (n=2977, mean age 62.5 years), higher baseline HbA1C levels were associated 
with lower cognitive function in subjects with diabetes (Cukierman-Yaffe et al. 
2009). Subjects in the ACCORD-MIND study were subsequently divided into two 
groups, with 1,378 individuals receiving intensive treatment targeting HbA1C levels 
below 6.0% and 1,416 receiving standard treatment targeting HbA1C levels between 
7.0%–7.9%. After a follow-up of 40 months, those who had received intensive 
treatment had a greater total brain volume than to those who had received standard 
treatment. However, no signifi cant difference in cognitive function was reported 
between the groups. It is also noteworthy that intensive treatment was associated 
with increased mortality, which led to an end to intensive treatment (Launer et al. 
2011). In the large Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modifi ed Release Controlled Evaluation (ADVANCE) trial, subjects with type 2 
diabetes mellitus (n=11140, aged 55 years or more at entry) were divided into two 
groups, with one group receiving intensive and the other standard treatment, and 
the participants were followed up for a median of 5 years. The results showed no 
signifi cant differences between the groups in regard to cognitive decline or diagnosed 
memory illnesses (ADVANCE Collaborative Group et al. 2008). 
The effect of diabetes on cognition is probably multifactorial. Chronic 
hyperglycaemia may promote cerebrovascular disease, but recurrent episodes of 
hypoglycaemia may also have a negative effect on cognitive function. Other proposed 
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mechanisms of diabetes on cognitive function are infl ammatory mediators, 
rheological factors and dysregulation of the endocrine system (Strachan et al. 2011). 
2.1.4 CHOLESTEROL AND COGNITION 
In large studies, high blood cholesterol in midlife has been indicated as a risk factor 
for developing a memory illness in late life (Kivipelto et al. 2001, Whitmer et al. 
2005, Solomon et al. 2009). This relationship between cholesterol and cognitive 
decline seems to alter with aging, as is also the case with blood pressure. In one 
population-based study (n=1449), at an average of 21 years’ follow-up, high serum 
total cholesterol in midlife was associated with  the risk of memory illness in late life, 
but declining levels of total cholesterol with aging were associated with an elevated 
risk of cognitive decline (Solomon et al. 2007). However, in another study, high 
cholesterol in midlife did not elevate the risk of cognitive decline in later life, but a 
decrease in cholesterol levels over time increased the risk of developing a memory 
illness (Mielke et al. 2010). In late life, high serum total cholesterol levels have been 
associated with a reduced risk of memory illness (Mielke et al. 2005). 
Growing evidence suggests that statin use is associated with a lower incidence of 
cognitive impairment. A recent meta-analysis of eight prospective studies (including 
57,020 participants and 2,851 cases) investigated the relationship of statin use and 
the risk of memory illness, and a signifi cant association between statin use and a 
reduced risk of memory illness was found. The summative relative risk of memory 
illness for statin use was 0.62 (95% CI 0.43–0.81)(Song et al. 2013). Statin therapy 
for memory illness has been investigated in a few interventional trials, and so far the 
evidence is insuffi cient to support statin therapy as a treatment for memory illness 
(Simons et al. 2002, Sparks et al. 2005, Feldman et al. 2010).  A Cochrane review 
assessed statin treatment for patients with a diagnosed memory illness, and the 
results showed no benefi t of statin therapy on cognition (McGuinness et al. 2013) . 
2.1.5 SMOKING AND COGNITION 
Smoking has been recognised as a cardiovascular risk factor beyond doubt. A review 
including 23 longitudinal studies showed that smoking increases the risk of memory 
illness in older people. In this review, fi ve studies found a signifi cant link between 
current smoking and an increased risk of incident memory illness, seven studies 
found a signifi cant link with an increased risk of cognitive decline, one established 
a signifi cant link between memory illness and past or current smoking, and no 
studies reported a signifi cant link between former smoking and incident cognitive 
decline or dementia. In a meta-analysis of these 23 studies, the summative ratios 
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of current smokers versus never- or non-smokers were 1.59 (95% CI 1.15–2.20) 
for AD, 1.35 (95% CI 0.90–2.02) for VaD, 1.16 (95% CI 0.90–1.50) for unspecifi ed 
memory illness, and 1.20 (95% CI 0.90–1.59) for cognitive decline. These results 
support the notion that smoking cessation in older age may have a preventive effect 
on cognitive impairment (Peters et al. 2008) . 
2.2 ALZHEIMER’S DISEASE AND CARDIOVASCULAR RISK   
 FACTORS 
AD is the most common disease causing cognitive impairment (Reitz et al. 2011) and 
the fi fth leading cause of death amongst persons aged 65 and older in the United 
States (Alzheimer´s Association et al. 2011). Typical neuropathological fi ndings of an 
AD-affected brain are diffuse and neuritic extracellular amyloid plaques (Reitz et al. 
2011). There is growing evidence of the vascular contribution to the aetiology of AD. 
At autopsy, cerebral white matter changes – a sign of cerebrovascular disease – are 
associated with AD pathology (Moghekar et al. 2012). Traditional cardiovascular 
risk factors such as hypertension in midlife, hyperlipidemia, diabetes and smoking 
increase the risk of developing AD (Breteler 2000, Purnell et al. 2009, Qiu 2012). 
In a Chinese longitudinal study (n=837) amongst patients with mild cognitive 
impairment (MCI), vascular risk factors increased the risk of MCI conversion to 
AD while treatment of vascular risk factors decreased the risk of MCI conversion 
to AD (Li et al. 2011). In one study (n=134), MCI patients with elevated blood 
levels of midregional proatrial natriuretic peptide (MR-proANP) who were treated 
with antihypertensive medication, the risk of developing AD was reduced by 36% 
(Schneider et al. 2011). High pulse pressure, a sign of arterial stiffness, has also 
been linked to AD in older people (Qiu et al. 2003). On the other hand, in one 
study, increased white matter changes were associated with aging and a decline 
in executive function, but these did not affect AD-specifi c pathologic progression 
– suggesting that the vascular contribution to AD dementia is probably additive 
though not necessarily independent of the amyloid pathway (Lo et al. 2012). 
2.2.1 HYPERTENSION AND AD 
Midlife hypertension increases risk of hippocampal atrophy, an area typically 
affected by AD (Korf et al. 2004), and of developing AD in late life (Kivipelto et al. 
2001, Kivipelto et al. 2005). Existing data supports the role of oxidative stress and 
infl ammation as underlying factors behind vascular complications and worsening 
brain perfusion, leading to the progression of AD (Feldstein 2012). Hypertension in 
midlife may cause leakage of the blood-brain barrier and lead to the extravasation 
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of proteins in brain tissue (Kalaria 2010). Protein extravasation may cause the 
accumulation of amyloid beta-peptides by neuroinfl ammation, disconnection 
between the cerebral blood fl ow and metabolism, altered synaptic transmission, 
neuronal injury, and amyloid deposition into parenchymal and neurovascular 
lesions (Deane et al. 2004).  
The main pathological fi ndings in AD are the accumulation of β-Amyloid 
peptide in diffuse and neuritic plaques, the accumulation of hyperphosphorylated 
tau intracellularly, and a diffuse loss of neurons and synapses (Reitz et al. 2011). In 
the Honolulu Asia Aging Study, elevated blood pressure in midlife and low plasma 
levels of β-Amyloid, a vasoactive protein, were associated with late-life AD (Shah 
et al. 2012). The association between high blood pressure and AD diminishes with 
aging. In a French study, a signifi cant decrease in blood pressure was reported in 
patients with diagnosed Alzheimer’s disease during one-year follow-up (n=327), 
and the largest decrease in blood pressure was observed in patients with the most 
severe impairment in dementia at baseline. The authors suggest that a blood 
pressure decrease seems to be mainly a secondary phenomenon in AD (Hanon et 
al. 2005b). A suggested explanation for this observation has been that a decrease 
in blood pressure following the onset of AD is result of weight loss and changes in 
the autonomic regulation of blood fl ow (Reitz et al. 2011). In a longitudinal study 
(n=1259) covering 7 years of follow-up, hypertension in people aged over 65 was 
not associated with AD (Posner et al. 2002).  
2.2.2 DIABETES AND AD 
There is growing evidence that diabetes is a risk factor for AD. In a meta-analysis 
of 19 studies including 6,184 subjects with diabetes and 38,530 subjects without 
diabetes, the risk ratio for developing AD amongst patients with diabetes was 1.46 
(95% CI 1.20–1.77) (Cheng et al. 2012). In another meta-analysis, 15 epidemiological 
studies were analysed and 14 of them reported a positive association between DM II 
(diabetes mellitus type 2) and AD (Vagelatos and Eslick 2013). Of these 14 studies, 
the association was statistically signifi cant in nine of them. In a large population-
based cohort study (n= 615,529 diabetic patients and 614,871 age- and sex-matched 
controls), diabetes increased the risk of AD in both sexes and all ages (Wang et al. 
2012). In a follow-up study (n=3139), insulin resistance was associated with a higher 
risk of AD for three years after baseline, but the risk was no longer increased after 
three years. The authors suggested that insulin metabolism infl uences the clinical 
manifestation of AD only within three years (Schrijvers et al. 2010).  
Possible explanations for the relationship between diabetes and AD have been 
discussed. Type 2 diabetes as well as obesity are associated with insulin resistance. 
Insulin resistance may increase the levels of β-Amyloid peptide in the brain (Craft 
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2007) and thus have a role in the pathogenesis of AD. Insulin competes with 
β-Amyloid for insulin degrading enzyme and hinders the clearance of β-Amyloid 
peptide from the brain (Craft 2007). Diabetes enhances the formation and 
accumulation of advanced glycation end products (AGEs). Neurofi brillary tangles 
(NFTs) and senile plaques found in patients with AD contain receptors for AGEs 
(Yamagishi et al. 2005). An increased expression of AGE receptors is detected in 
an AD-affected brain, and AGE receptors may facilitate neuronal damage caused 
by β-Amyloid peptide (Yan et al. 1996). 
2.2.3 BODY WEIGHT AND AD 
Results on the association between obesity and AD are confl icting. In a follow-up 
study lasting up to 18 years (n=382), which was not included in the meta-analysis 
described below, excess body weight amongst older women was a risk factor for 
AD. A similar association was not found in men (Gustafson et al. 2003). A meta-
analysis including 6 studies examining obesity and 10 studies examining diabetes in 
relation to the risk of AD showed that obesity increased the risk of AD by 59% and 
diabetes increased the risk by 54% (Profenno et al. 2010). On the other hand, there 
are studies that link low body weight to AD. In a small study with 74 participants 
(58 AD patients and 16 controls), there was an association between low body weight 
and atrophy of the mesial temporal cortex in AD patients (Grundman et al. 1996). 
In another follow-up study spanning 32 years, a loss of body weight preceded the 
clinical onset and diagnosis of both AD and vascular dementia (Stewart et al. 2005). 
2.2.4 LIPID PROFILE AND AD 
Apolipoprotein E (apoE) is a cholesterol carrier and supports lipid transfer and injury 
repair in the brain. Apo-E is expressed in humans in three different alleles. People 
carrying the APOE ε4 allele are at an increased risk of AD compared to carriers of 
the more common ε3 allele, whereas the ε2 allele seems to reduce the risk of AD 
(Liu et al. 2013). Carriage of the ε4 allele is linked to an increased risk of amyloid 
angiopathy and cognitive decline amongst the aging (Liu et al. 2013). The presence 
of a single ε4 allele increases the risk of AD 2–3-fold, while ε4-homozygosity induces 
a 5-fold increase in the risk of developing AD (Reitz et al. 2011).  
The relationship between plasma lipid levels and AD is less clear, though there 
is growing evidence concerning the role of lipid metabolism in the pathogenesis 
of AD (Mielke and Lyketsos 2006). Studies have shown that elevated cholesterol 
levels in midlife increase the risk of developing AD (Solomon et al. 2009, Kivipelto 
et al. 2005). In a population aged 65 years or more (n=2141), no correlation was 
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present between total cholesterol (TC) or high-density lipoprotein (HDL) and AD 
(Li et al. 2005), whereas the Apo-Eε 4 allele showed a typical association with 
AD. The authors suggested that an increased risk of AD with APOE ε4 is probably 
not mediated by serum TC levels (Li et al. 2005). In a Swedish prospective study 
conducted amongst women aged 38–60 years (n=1462), no association between 
midlife cholesterol levels and the risk of AD was observed (Mielke et al. 2010). In 
one study, the lipid profi le of AD patients (n=153) was investigated and compared to 
non-demented subjects with atherosclerotic disease (n=25). In this study, elevated 
levels of total cholesterol, low-density lipoprotein (LDL) and triglycerides, and a 
normal high-density lipoprotein and TC/HDL ratio characterised the lipid profi le in 
AD patients, which has several similarities to the cardiac risk profi le (Sabbagh et al. 
2004). In another study, subjects with AD (n=148) presented with higher LDL and 
TC and lower HDL levels than the control subjects (n=198) (Warren et al. 2012). 
2.2.5 SMOKING AND AD 
The association between smoking and the risk of AD is unclear. Some prospective 
studies have found no association between smoking and the risk of developing AD 
(Doll et al. 2000, Hebert et al. 1992), while other studies have even shown that 
smoking may associate with a reduced risk of AD (Brenner et al. 1993, Tyas 1996). 
However, there are also reports that link smoking and AD.  There are prospective 
studies in which smoking was found to increase the risk of developing AD (Merchant 
et al. 1999, Ott et al. 1998). In a follow-up study (n=3734), midlife smoking increased 
the risk of AD, and the risk was dependent on the amount of tobacco smoked (Tyas 
et al. 2003). Furthermore, a large population-based study (n=21123) demonstrated 
a smoking-related increased risk of developing AD (HR, 2.57; 95% CI, 1.63–4.03) 
(Rusanen et al. 2011). 
2.3 VASCULAR DEMENTIA AND CARDIOVASCULAR RISK   
 FACTORS 
2.3.1 BLOOD PRESSURE AND VAD 
VaD is the second most common form of memory illness after AD (Stephan and 
Brayne 2008, Fratiglioni et al. 2000). VaD is typically a cerebrovascular disease 
resulting from disrupted circulation or perfusion in different brain regions. 
Radiologically, infarcts of large vessels as well as small vessel disease can be detected 
(Roman et al. 1993). As the blood pressure increases with age, both rising systolic and 
rising diastolic blood pressure are associated with accelerated brain ageing and an 
increased risk of stroke. Although many studies show a link between dementia and 
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blood pressure, most of them do not distinguish VaD from other types of dementia 
(Peters 2012). However, there are some epidemiological studies that support a link 
between blood pressure in midlife and VaD, but some studies also fi nd a similar 
link in late life. In a population-based case-control study (129 patients with VaD 
and 535 control subjects), the risk of VaD was not related to current hypertension 
or orthostatic hypotension, but a history of arterial hypertension doubled the 
risk of VaD (Lindsay et al. 1997). In a Japanese follow-up study amongst elderly 
people (n=668, midlife blood pressure data was available for 534 subjects), midlife 
hypertension increased the risk of VaD approximately 5-fold, regardless of late-life 
blood pressure levels. Furthermore, late-life hypertension was also associated with 
an increased risk of developing VaD. In this study, it is notable that no association 
between midlife or late-life hypertension and AD was found (Ninomiya et al. 2011). In 
a longitudinal study amongst elderly subjects covering 7 years of follow-up (n=1259), 
a history of hypertension was associated with an increased risk of VaD but not AD. 
The independent association between hypertension and VaD was weak, but the co-
existence of hypertension with heart disease increased the risk of developing VaD 
threefold, and with diabetes the risk was sixfold (Posner et al. 2002).  
Severe or moderate white matter hyperintensities are considered as criteria 
for subcortical VaD (Erkinjuntti et al. 2000). Hypertension has been recognised 
as a key risk factor for brain white matter hyperintensities (van Dijk et al. 2004, 
Gottesman et al. 2010, Wardlaw et al. 2013).  In a study with four-year follow-
up (n=845) in subjects aged 59–71 years at entry, hypertension was a major risk 
factor for severe white matter hyperintensities. Taking antihypertensive medication 
with controlled blood pressure reduced the risk of white matter hyperintensities 
(Dufouil et al. 2001). In one study, an increase in white matter hyperintensities and 
progressive whole-brain atrophy were associated with hypertension in older people 
(Firbank et al. 2007). In an investigation of the third generation of the Framingham 
Heart Study (n=579, mean age 39.2 years), increased systolic blood pressure was 
associated with vascular brain injury even in young adults (Maillard et al. 2012). 
In another study, past and present blood pressure were evaluated over a 20–year 
period (n=1077) amongst non-demented elderly subjects. Both high and declining 
diastolic blood pressure were found to associate with global brain atrophy on MRI 
(Heijer et al. 2003). There is also evidence that cerebral perfusion is reduced in white 
matter hyperintensities, exposing these areas to transient ischaemia (Marstrand 
et al. 2002). Hypertension, white matter lesions and stroke may have combined 
or cumulative effects, and these factors accumulate with aging ((Peters 2012). In 
a population-based study (n=1077) amongst people aged 60 to 90 years, it was 
demonstrated that a silent brain infarct was present in magnetic resonance imaging 
in 20% of the study population. (Vermeer et al. 2002).  As vasculature stiffening 
increases with aging, the stiffening vasculature leads to more pulsatile fl ow and 
lower diastolic blood pressure. This may lead to hypoperfusion in high-fl ow organs 
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such as the brain (Mitchell 2008). There is evidence that, in older people, the 
severity of white matter lesions is associated with the lability of blood pressure in 
midlife (Havlik et al. 2002). Other proposed mechanisms by which hypertension 
may increase the risk of VaD are damage to the blood–brain barrier, degeneration 
of cerebral capillaries, and an increased risk of stroke (Peters 2012).  
2.3.2 DIABETES AND VAD 
Diabetes seems to be a risk factor for VaD. In a study of 593 patients, data on 
subjects with VaD (n=63) was retrospectively analysed and a history of pre-morbid 
diabetes was associated with an earlier onset and faster cognitive deterioration in 
VaD (Murthy et al. 2010). In the Vantaa 85+ Study (n=553) amongst people aged 
85 years or over, diabetes doubled the incidence of VaD and AD (Ahtiluoto et al. 
2010). In a review article providing an overview of the relationship between DM II 
and two subtypes of memory illness, VaD and AD, a clear link between DM2 and 
VaD was detected (Exalto et al. 2012). It can be concluded that DM2 and VaD are 
associated and that this association seems to be primarily due to cerebrovascular 
changes. 
2.3.3 LIPID PROFILE AND VAD 
The relationship between serum lipid levels and VaD is not clear. In a large cohort 
study of 9,844 participants, an even moderately elevated level of serum cholesterol in 
midlife increased the risk of VaD and AD (Solomon et al. 2009). On the other hand, 
there are also negative results with regard to the relationship between cholesterol and 
VaD. In a review article, 18 studies on the relationship between total cholesterol and 
dementia were investigated. Out of these 18 studies, 4 investigated the association 
between total cholesterol and the risk of VaD. Only one study included participants 
in their midlife. In these four studies, no signifi cant association was found between 
total cholesterol and VaD (Anstey et al. 2008). 
2.3.4 SMOKING AND VAD 
Results on the link between smoking and vascular dementia show evidence of 
an increased risk of developing VaD amongst smokers. However, most studies 
on smoking and cognitive decline do not report the type of memory illness. In a 
systematic meta-analysis including 19 follow-up studies, smokers were at an elevated 
risk of developing VaD (RR 1.78; 95% CI 1.28–2.47) (Anstey et al. 2007). Another 
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meta-analysis found no signifi cant correlation between smoking and the risk of 
VaD (RR 1.35; 95% CI 0.90–2.02) (Peters et al. 2008). In a large population-based 
study (n=21123), smoking signifi cantly increased the risk of developing VaD (RR 
2.72; 95% CI 1.20–6.18) (Rusanen et al. 2011). 
2.4 DEMENTIA WITH LEWY BODIES AND CARDIOVASCULAR  
 RISK FACTORS 
 DLB is the second most common cause of neurodegenerative dementia in older 
people. The disease is characterised by fl uctuating symptoms as well as visual 
hallucinations and extrapyramidal signs (McKeith et al. 2000, McKeith et al. 2004). 
Typical pathological fi ndings in DLB are protein inclusions in neurons (Lewy bodies, 
LB) and dystrophic neurites containing pathologic alpha-synuclein (Jellinger 2009). 
The prevalence of DLB has varied in different studies between 0% and approx. 20% 
of all dementia cases. In a recent review study comprising all relevant population 
and clinical studies, the prevalence of DLB accounted for 4.2% of all diagnosed 
dementias in the community (Vann Jones and O’Brien 2013).  
Studies done on cerebrovascular disease and DLB are very few. Most of them 
are post-mortem studies and conducted with a very limited number of subjects. No 
convincing evidence linking DLB and cardiovascular risk factors can be presented. In 
a small post-mortem study, brain mini-bleeds were more common in DLB patients 
(n=20) than in age-matched controls (n=14)(De Reuck et al. 2013). The authors 
suggested that mini-bleeds are related to a destruction of the blood–brain barrier 
related to a neurodegenerative process. No other cerebrovascular lesions prevailed in 
the brains of individuals with DLB. In another small post-mortem study with a small 
number of DLB patients (n=8), cerebral mini-bleeds and a history of hypertension 
were more frequent amongst patients than in controls (n=10) (De Reuck et al. 
2011). The impact of AD pathology and vascular pathology on the progression of 
neurodegeneration and cognitive decline is not well understood.  In one post mortem 
study AD related lesions in progression of DLB appeared to be largely independent 
from coexistent vascular pathology. The authors suggested that AD-type pathology, 
but not vascular pathology, plays a key role in neurodegeneration leading to cognitive 
decline in DLB (Jellinger and Attems 2008). In another post-mortem study (1,339 
cases and 486 age-matched controls), cardiovascular lesions were more common in 
AD and DLB patients than in controls, but cardiovascular lesions were not associated 
with cognitive function (Jellinger 2010). In a post-mortem study with 96 subjects 
with DLB, the frequency of cerebrovascular lesions of various intensity was even 
lower than in age-matched controls (Jellinger 2003).   
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2.5 OVERLAPPING PATHOLOGIES IN MEMORY ILLNESSES 
Within the context of pathophysiological mechanisms, memory illnesses represent a 
heterogeneous group of diseases. The speed and rate of the progression of cognitive 
decline may also vary between individuals. To make matters even more complicated, 
it is not unusual that more than one underlying pathophysiological mechanism is 
at play in the case of cognitive decline in older people. It is rather common that 
a memory illness is a mixed dementia with a co-existing combination of a VaD 
pathology and AD/and or Lewy pathology (Jellinger 2013, Schneider et al. 2007, 
Bacchetta et al. 2007). It was reported in one study that vascular pathology is so 
common that a pure AD pathology was observed only in 21% cases of subjects with 
memory illnesses (Fernando et al. 2004). The proportion of mixed pathologies seems 
to increase with aging (James et al. 2012). However, the concept and diagnosis of 
mixed dementia is not simple, as it is diffi cult to identify the type and regions of 
cerebrovascular disease responsible for causing dementia (Meguro et al. 2012). In a 
recent review article, the authors suggested that – due to the frequent co-existence 
of AD and small vessel disease (SVD) in the brain – SVD is a risk factor for AD. 
They also found that the most common form of vascular pathology in VaD patients 
was infarcts, due to atherosclerosis and embolic events (Thal et al. 2012).  
2.6  NATRIURETIC PEPTIDES 
A- and B-type natriuretic peptides are cardiac hormones (Goetze 2004). A-type 
natriuretic peptide (ANP), initially named cardionatrin, was fi rst found in the 
early 1980s (de Bold et al. 1981). ANP is primarily secreted from the atria. B-type 
natriuretic peptide (BNP) was fi rst found in the porcine brain and was therefore 
initially termed ‘brain natriuretic peptide’ (Sudoh et al. 1988). Later, it was discovered 
that BNP is a heart hormone secreted from the ventricles and also from atria.  
In a situation of increased cardiac wall stress, the secretion of BNP mainly takes 
place in the ventricles. ANP is stored in granules and released with even minor 
triggers, such as exercise. BNP, for its part, has minimal storage in granules and 
is synthesised and secreted in bursts (Daniels and Maisel 2007). As a response 
to stretch caused by volume and pressure overload, cardiac myocytes produce 
108-amino acid prohormone proBNP which is further cleaved to 32-residue 
BNP and 76-residue N-terminal fragment of proBNP (NT-proBNP). ANP is fi rst 
produced as 126-amino acid proANP which is further cleaved to 98-residue ANP and 
28-residue N-terminal fragment of proANP (NT-proANP). In addition to volume 
and pressure overload, hypoxia, tachycardia, angiotensin II and cytokines can also 
modulate cardiac natriuretic peptide production (Vuolteenaho et al. 2005, Thibault 
et al. 1999).  
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The heart is a partly self-regulated pump. In the short term, the heart responds 
to increased demand by increasing the stroke volume and heart rate. Prolonged 
heart overload leads to cardiac remodelling such as hypetrophy, loss of myocytes 
and increased interstitial fi brosis. This remodelling may be a consequence of 
several conditions such as hypertension, valvular disease or myocardial infarction 
(Vuolteenaho et al. 2005). Natriuretic peptides have several mechanisms that aim 
to reduce cardiac load. Natriuretic peptides relax vascular smooth muscle and 
thus lower blood pressure by increasing the diameter of blood vessels. BNP and 
ANP enhance the excretion of water and salts to urine, resulting in reduced fi lling 
of the heart and lowered blood pressure. Natriuretic peptides inhibit the renin-
angiotensin-aldosterone system, which results in lower blood pressure. Natriuretic 
peptides also inhibit cardiac hypertrophy and fi brosis (Vuolteenaho et al. 2005).  
ANP and BNP as well as their receptors are widely distributed in the brain, 
spinal cord and pituitary, as well as the kidneys, adrenal gland and vasculature, in 
addition to the heart (Richards 2007). The effects of ANP and BNP are mediated 
by the same receptor, natriuretic peptide receptor-A (NPR-A).  NPRs are linked to 
a cyclic guanosine monophosphate-dependent signalling cascade. The clearance of 
natriuretic peptides from the blood is mediated by NPR-C, which also regulates the 
circulating levels of natriuretic peptides. In addition, BNP is degraded by neutral 
endopeptidase, a specifi c enzyme which opens the ring structure and inactivates the 
peptide. However, direct renal fi ltration and passive excretion may also infl uence 
BNP clearance (Vuolteenaho et al. 2005, Daniels and Maisel 2007, Koller and 
Goeddel 1992). The half-life of BNP is approximately 20 minutes as it is quickly 
cleared from the blood. NT-proBNP has a longer half-life of approximately 1 to 2 
h, which leads to higher circulating levels and lower fl uctuation of blood levels than 
with BNP (Daniels and Maisel 2007).  
Figure 1. Regulation and effects of cardiac natriuretic peptides. Black arrows denote stimulation and grey 
arrows inhibition (modiﬁ ed from Vuolteenaho, Ala-Kopsala and Ruskoaho 2005). 
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 Natriuretic peptides have established their clinical use in the diagnostics of 
dyspnoea patients.  In acute dyspnoea, elevated blood levels of BNP and NT-proBNP 
point to a cardiac origin of symptoms. Such cardiac conditions as heart failure 
and acute coronary syndrome may elevate the levels of natriuretic peptides. In 
patients with acute myocardial infarction, increased levels of natriuretic peptides 
may refl ect the degree of left ventricular dysfunction (Daniels and Maisel 2007, 
Morita et al. 1993).  
Plasma levels of BNP are also known to increase with age, and higher levels are 
detected in female as compared to male individuals (Redfi eld et al. 2002).  Reasons 
such as renal impairment and a reduction of NPR-C receptors have been suggested 
to explain the elevation in the levels of natriuretic peptides with aging (Kawai et al. 
2004). It has been proposed that the higher levels of circulating natriuretic peptides 
in women are associated with oestrogen.  Renal dysfunction is known to increase 
the levels of natriuretic peptides. There are multiple possible explanations for this. 
Patients with chronic renal dysfunction tend to have higher atrial pressure, systemic 
pressure, and ventricular mass, all of which could stimulate the synthesis and release 
of cardiac peptides. Patients with renal disease may also have increased levels due to 
decreased renal fi ltration, decreased clearance by NPR-C and endopeptidases within 
renal tissue, or decreased renal responsiveness to BNP (Daniels and Maisel 2007). 
The clearance of NT-proBNP is not mediated by NPR-C or neutral endopeptidase 
but by glomerular fi ltration alone, and thus the levels of NT-proBNP may be more 
sensitive to renal fi ltration than those of BNP (Lamb et al. 2006).   
Obesity is associated with lower levels of BNP, which has been observed in 
subjects with and without heart failure. Various reasons have been proposed for 
this body-weight-related inverse correlation. One explanation may be increased 
clearance in obese patients (Daniels et al. 2008, Wang et al. 2004b, Daniels et al. 
2006). On the other hand, there is a study where BNP and NT-proBNP are more 
closely associated with lean mass than with fat mass. The authors of this study 
concluded that these fi ndings do not support the hypothesis that the lower BNP 
levels seen in obesity are driven by enhanced BNP clearance mediated via NPR-C 
(Das et al. 2005). 
2.6.1 NATRIURETIC PEPTIDES AND COGNITION 
In recent years, the association between cognitive decline and natriuretic peptides 
has been addressed in a few studies. A summary of reports investigating the 
relationship between natriuretic peptides and cognition is presented in Table 2. 
The association was fi rst demonstrated in patients with cardiovascular disease. 
The fi rst study to investigate the relationship between BNP and memory illness 
was published in 2006. In this study, BNP was linked with cognitive dysfunction in 
33
older adults (n=56) with a documented history of cardiovascular disease (Gunstad 
et al. 2006). Following the fi rst report, this fi nding has received support from other 
studies. In a sub-study of the population-based Hoorn study (n=313), non-demented 
individuals aged 59–87 years at baseline were enrolled in order to investigate the 
possible association of heart failure and reduced cognitive function. The main 
fi nding was that impaired cognitive function was observed in early stages of left 
ventricle dysfunction and that BNP levels were most strongly associated with late-
life cognitive performance (van den Hurk et al. 2011). In an Italian study (n= 60), 
BNP correlated with mini-mental state examination (MMSE) results in patients with 
heart failure (Feola et al. 2007). In a Swedish study, plasma BNP levels were elevated 
in patients with diagnosed subcortical VaD (n=15) but not in patients with AD (n=19) 
(Kondziella et al. 2009). In a group of patients (n=42) with diagnosed memory 
illness but no cardiovascular disease, BNP levels were associated with cognitive 
function but ANP levels were not (Naito et al. 2009). Furthermore, in a study with 
94 patients with probable AD and 53 healthy control subjects, concentrations of 
midregional pro-atrial natriuretic peptide (MR-proANP) were signifi cantly higher 
in the AD patients than in the controls (Buerger et al. 2009). 
Further on in another study, MR-proANP predicted the conversion of mild 
cognitive impairment (MCI) to AD (Buerger et al. 2011). NT-proBNP levels were 
signifi cantly associated with poor cognitive function in community-dwelling older 
adults (n=950) (Daniels et al. 2011).  
 Our research group has previously reported that BNP was an independent 
predictor of cognitive decline in the present study population of older individuals 
(Kerola et al. 2010).  In one study, three cohorts were formed – very mild dementia, 
MCI and AD – and BNP was associated with a diagnosis of disorder affecting 
cognition in all three cohorts (Hu et al. 2012). In a recent study, subclinical markers of 
cardiac stress, including NT-proBNP and generalised atherosclerosis, was associated 
with cognitive decline in older patients with DM II (n=831) (Feinkohl et al. 2013). 
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Table 2. Previous studies investigating natriuretic peptides and cognitive decline 
Author and 
year N 
Age of participants 
(years) Main outcome 
Gunstad & al. 
2006 56  mean age 70±8  
BNP predicted cognitive dysfunction in older adults 
with cardiovascular disease 
Feola & al. 
2007 60 mean age 65.5 
cognitive function correlated with BNP and 
advanced age 
Kondziella & 
al. 2009 53 
mean age 69±1.9 VaD, 
71±1.3 AD and 69±1.5 
controls 
Elevated BNP levels were associated with 
subcortical VaD but not with AD 
Naito & al. 
2009 42 mean age 74±1 
BNP levels correlated with cognitive function in 
demented patients 
Buerger & al. 
2009 147 
mean age 65.5±7.5 
controls and 73.9±8.0 
AD 
Increased MR-pro ANP levels were observed in AD 
patients compared to controls 
Buerger & al. 
2010 134 
mean age 64.3±9.0 
MCI-stable; 74.1±5.9 
MCI-AD; 73.1±9.4 MCI 
other 
MR-pro ANP predicted MCI conversion to AD 
Kerola & al. 
2010  464 mean age 80.0 
BNP predicted cognitive decline and new onset of 
memory illness in elderly general population 
Daniels & al. 
2011 950 
mean age 74.9±8.2 
NT-proBNP low and 
82.8±6.6 NT-proBNP 
high 
NT-proBNP levels had strong association with poor 
cognitive function 
van den Hurk 
&al. 2011 313 
mean age 67 (range 
59–87 years) 
early left ventricle dysfunction and higher BNP 
were associated with worse cognitive function 
Hu & al. 2012 600 
mean age 68.30 
(10.87SD) normal; 
72.38 (8.60) MCI; 
70.83 (11.69) AD; 
65.14 (9.80) other 
dementias 
BNP was associated with MCI, AD and very mild 
dementia 
Feinkohl & 
al. 2013 831 mean age  67.7±4.2 
cognitive decline was signiﬁ cantly associated with 
NT-proBNP and other markers of cardiac stress in 
patients with DM II 
BNP, B-type natriuretic peptide; AD, Alzheimer´s disease; VaD, vascular dementia, MCI, mild cognitive 
impairment; MR-pro ANP, mid-regional pro atrial natriuretic peptide; NT-proBNP, N-terminal fragment 
of proBNP; SD, standard deviation; DM II, diabetes mellitus type 2 
2.6.2 NATRIURETIC PEPTIDES AND MORTALITY 
The prognostic power of BNP on mortality has been addressed in previous studies. 
The results have been constant in various study settings with various selection 
protocols for the subjects, as BNP has maintained its status as a harbinger of 
increased mortality. In subjects without heart failure (n=3346) as a part of the 
Framingham Heart Study, the relationships of plasma BNP and NT-proANP with 
the risk of death from any cause as well as a fi rst major cardiovascular event, 
incident of heart failure, atrial fi brillation, stroke or transient ischaemic attack and 
coronary heart disease were examined. Both natriuretic peptides predicted the risk 
of death and cardiovascular events, with the exception of coronary heart disease, 
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after adjustment for traditional risk factors. It is noteworthy that, in this study, the 
levels of natriuretic peptides that predicted an increased risk of mortality were well 
below the threshold levels used in the diagnosis of heart failure (Wang et al. 2004a). 
In a Danish population-based prospective study on 764 participants aged 50 to 
89, NT-proBNP levels were a strong predictor of fi rst major cardiovascular event and 
mortality even after adjustment for traditional cardiovascular risk factors (Kistorp et 
al. 2005). In general practice outpatients (n=3123), BNP levels predicted the risk of 
cardiovascular events other than coronary heart disease events and of cardiovascular 
and all-cause mortality (Tsuchida and Tanabe 2008). In the Rancho Bernardo Study 
with 957 older adults, elevated plasma NT-proBNP levels predicted both all-cause 
and cardiovascular mortality (Daniels et al. 2008). In one study amongst elderly 
individuals with and without overweight/obesity (n=1606), BNP levels were higher 
in the subgroup without overweight/obesity, which is in line with earlier studies on 
BNP and obesity. BNP was an independent predictor of mortality when adjusted 
with body mass index (BMI) (Beleigoli et al. 2013).   
In dyspnoea patients (n=452), BNP was a strong independent predictor of long-
term mortality with non-cardiac and cardiac causes of acute dyspnoea (Christ et al. 
2007). Comparisons between different subtypes of natriuretic peptides as diagnostic 
and prognostic markers have been carried out in several studies, and in recent 
reports, no subtype of natriuretic peptides has shown clear superiority over others. 
In one study, the diagnostic properties of four subtypes of natriuretic peptides 
(proBNB, BNP, NT-proBNP and MR-proANP) were compared in patients with acute 
dyspnoea. All natriuretic peptides showed similar diagnostic performance. For long-
term mortality, low MR-proANP exhibited the strongest association with fi ve-year 
survival(Seronde et al. 2013). In another study, the prognostic power for mortality, 
MR-proANP, NT-proBNP and BNP were tested in community-dwelling subjects 
aged 70 years (n=999). MR-proANP levels in an elderly community population 
are, to a similar extent as the B-type natriuretic peptides, related to manifestations 
of cardiovascular disease. NT-proBNP provided the strongest predictive value for 
cardiovascular and all-cause mortality (Eggers et al. 2013). Although natriuretic 
peptides predict the prognosis independently of other risk markers in prospective 
studies, it is not yet recommended to use the measurement of natriuretic peptides 
for the risk assessment of cardiovascular disease in asymptomatic adults (Greenland 
et al. 2010).  
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2.7 COGNITIVE DECLINE AND MORTALITY 
2.7.1 MMSE SCORE 
MMSE was developed for grading cognitive state (Folstein et al. 1975). It is widely 
used as a screening method for memory illnesses and in monitoring changes in 
patients with a previous diagnosis of memory illness. The test includes nineteen 
different tasks, and the maximum score is 30. MMSE scores have been classifi ed 
as high normal (28–30), low normal (24–27), mild impairment (18–23) or severe 
impairment (0–17) (Bassuk et al. 2000) However, one has to bear in mind that the 
test is not diagnostic and several factors such as education (Ylikoski et al. 1992), 
state of alertness and other conditions such as infections may infl uence the result 
of the test. For example, a higher cut score has been proposed for individuals with 
an academic degree (O’Bryant et al. 2008, Spering et al. 2012). Age dependency has 
also been addressed in regard to performance in MMSE in both men and women 
(Dufouil et al. 2000). 
2.7.2 MEMORY ILLNESS AND MORTALITY 
Studies have shown that a memory illness increases mortality in the elderly. In 
a recent review regarding the survival of patients with various forms of memory 
illness, it was found that the median survival time from the age of dementia onset 
ranges from 3.3 to 11.7 years, with most studies falling within the 7–10-year range. 
The median survival time from the age of disease diagnosis ranged from 3.2 
to 6.6 years (Todd et al. 2013). The hazard ratios for AD mortality have ranged 
from 1.40 to 2.84 (Park et al. 2013). Moderate or severe memory illness predicts 
mortality, but results with mild cognitive impairment have been less clear. In a 
prospective cohort study including 3,957 older adults and using the Short Portable 
Mental Status Questionnaire for grading cognition, moderate and severe memory 
illness were independent predictors of mortality. However, in this study, mild 
cognitive impairment was not associated with mortality (Stump et al. 2001). In a 
longitudinal cohort study (n=2625), moderate and severe memory illness at baseline 
were associated with fi ve-year mortality risk (HR 2.41; 95%CI 1.74–3.34). In the 
group with mild cognitive impairment, an increased risk of death was also present 
but to a lesser degree than amongst those with more severe forms of memory 
illness (HR1.56; 95%CI 1.28–1.92) (Nguyen et al. 2003). The MMSE as well as 
cardiovascular risk factors and morbidity have been compared in regard to their 
independent prognostic value. In a Finnish study amongst older individuals (n=398) 
with stable cardiovascular disease (CVD), an MMSE score of less than 24 was a 
strong independent predictor of six-year mortality (HR 2.38; 95% CI 1.52–3.74) 
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(Strandberg et al. 2009). In a recent Korean follow-up study as part of the AGE study 
amongst an elderly population (n=2712), MMSE was an independent predictor of 
all-cause mortality after adjusting for socio-demographic factors and concomitant 
diseases. Mild cognitive dysfunction presented an HR of 1.93 (95%CI 1.43–2.60) 
and a moderate HR of 2.66 (95% CI 1.86–3.79). When various domains of the 
MMSE were further evaluated, calculation test-measuring attention (HR 1.48; 95% 
CI 1.16–1.89) and orientation to time (HR 1.39; 95%CI 1.07–1.80) demonstrated 
independent prognostic value for all-cause mortality (Park et al. 2013). In addition 
to predicting mortality, cognitive impairment may also anticipate cardiovascular 
events. In a large study (n=30,959), an independent association was discovered in 
a large high-risk CV population between MMSE score and myocardial infarction, 
stroke, hospital admission for heart failure and mortality and their CV composite 
(major CV events).Those with an MMSE score less than 24 had an increased risk 
of a major CV event compared to those with an MMSE score of 30 (HR: 1.35; 95% 
CI 1.21–1.50). The MMSE score was signifi cantly associated with the risk of stroke, 
congestive heart failure and CV death (O’Donnell et al. 2012). 
2.8 DEPRESSION AND MORTALITY IN THE ELDERLY 
Depressive symptoms are common in the elderly population (Arve et al. 2012). The 
prevalence of diagnosed depression in late life is estimated to exceed 10% (Beekman 
et al. 1999), making depression the most common mental health problem of older 
people (Baldwin 2000). In patients with coronary heart disease, it is estimated 
that 20% have major depression and another 20% suffer from minor depression 
(Carney and Freedland 2008). One study showed that depressive symptoms are 
common in patients with heart failure (n=572), with 41% of the subjects suffering 
from depressive symptoms (Lesman-Leegte et al. 2006).  
Earlier studies have demonstrated that depression increases the risk of mortality 
and cardiovascular morbidity amongst older people. In the Cardiovascular Health 
Study, a systematic review of 21 studies using depression diagnosis in a community-
dwelling elderly population, depression was associated with increased mortality (Saz 
and Dewey 2001). In another systematic review of the 61 reports included in the 
study, 44 reports introduced positive evidence of an association between depression 
and non-suicide mortality in older people (Schulz et al. 2002). A large Chinese 
cohort study on people age 65 or older (n=62839, 21473 men and 41366 women) 
investigated the association of depressive symptoms with CVD, stroke and coronary 
heart disease (CHD) mortality. The results showed that depressive symptoms were 
independently associated with higher CHD mortality in older men (HR 1.41; 95% 
CI 1.08–1.84) and with higher stroke mortality in both sexes (HR 1.02 per Geriatric 
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Depression Scale score, 95% CI: 1.00–1.04). Health status attenuated the association 
between depressive symptoms and mortality (Sun et al. 2013).   
In one recent study with a relatively large number of older adults (n=1226), 
the association between depression and mortality was once again demonstrated. 
Participants with major depression were at an increased risk of mortality compared 
to their non-depressed counterparts (HR 1.90; 95% CI 1.57–2.31). An interesting 
fi nding in this intervention study was that patients with major depression who got 
treatment were at no greater risk of mortality than were people without depression 
(HR 1.09; 95% CI 0.83–1.44) (Gallo et al. 2013). On the other hand, there are also 
controversial fi ndings concerning the possible connection between depression and 
prognosis. In a systematic review, the conclusion was that treatment of depression in 
patients with CVD is associated with modest improvement in depressive symptoms 
but no improvement in cardiac outcomes (Thombs et al. 2008). Depression has 
also been linked with poor treatment compliance of a co-existing somatic condition 
(Ciechanowski et al. 2000). In a study including 4,676 participants with a history of 
CHD (The REGARDS study), a higher risk of myocardial infarction (MI) or death 
was observed in participants with depressive symptoms (HR1.41; 95%CI 1.15–1.72) 
after adjusting for demographic data. When adjusted for behavioural mechanisms 
such as alcohol use, smoking, physical inactivity and medication non-adherence, the 
risk of MI or death was no longer signifi cantly associated with depressive symptoms 
(HR 1.14; 95%CI 0.93–1.40). These fi ndings suggest that behavioural mechanisms 
may play a signifi cant role in the prognosis of patients with CHD (Ye et al. 2013). 
Similar fi ndings were observed in a large prospective study (the Cardiovascular 
Health Study) with a cohort of 5,888 community-dwelling older adults estimating 
the risk of cardiovascular mortality associated with depressive symptoms due to 
physical inactivity. In the Cardiovascular Health Study, depressive symptoms were 
found to be an independent predictor of mortality in older adults (Schulz et al. 
2000). When it was further investigated whether physical inactivity is a mediator 
of increased risk of cardiovascular mortality, it was found that physical inactivity 
accounted for 25% of the increased risk of cardiovascular mortality (Win et al. 2011). 
In heart failure (HF) patients, depression has also been associated with an adverse 
prognosis. In a study with 204 HF patients, depression was associated with death or 
cardiovascular hospitalisation (HR 1.75; 95%CI 1.14–2.68) (Sherwood et al. 2007). 
In the COACH study, 958 patients hospitalised for HF were included.  Patients with 
severe depressive symptoms had a 40% higher risk for HF readmission or death 
(Lesman-Leegte et al. 2009). 
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3 AIMS OF THE STUDY 
The aim of the present study was to investigate the predictive value of BNP, a direct 
marker of cardiovascular stress, as well as of moderately attenuated MMSE score and 
depression for total and cardiovascular mortality when established cardiovascular 
risk factors were taken into account in an elderly population. Another important 
objective of the study was to evaluate how the association and predictive value of 
BNP for memory illness varies with aging and the progression of cognitive decline. 
 
The specifi c aims of the present study were: 
 1. To evaluate the prognostic power of BNP and moderately   
  attenuated MMSE score (18–23) as independent predictors  
  of total and cardiovascular mortality together with established  
  cardiovascular risk factors in an elderly population. 
 2. To evaluate whether the prognostic capacity of natriuretic   
  peptides with regard to memory illness depends on age.   
  In addition, a systematic assessment of the levels of   
  various natriuretic peptides in the main types of memory   
  illnesses has been lacking. Therefore, the aim was to analyse the  
  association of three natriuretic peptides (ANP, NT-proANP, and  
  BNP) with three classes of memory illnesses. 
 3.  To examine the relationship between the severity of memory  
  illness and levels BNP in an older general population.   
 4.  To test the independent and additive predictive value of   
  depressive symptoms and  BNP together with established   
  cardiovascular risk markers with regard to total and   
  cardiovascular mortality in a general elderly population. 
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Figure 2. Flow chart of the study 
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4.1 STUDY POPULATION 
This study is a part of the larger population-based, multidisciplinary Kuopio 75+ 
health study focusing on the clinical epidemiology of diseases, medications and 
functional capacity in older persons aged 75 years or older. The target population 
was an age-stratifi ed random sample (n=700) of all residents of the city of Kuopio 
in Eastern Finland who were aged 75 years or more on January 1st 1998 (n = 
4518). The cohort included 700 participants. Five persons could not be contacted, 
79 refused to take part in the study, and fi fteen died before the examination. The 
remaining 601 participants formed the study population.  
Written informed consent was obtained from the study participants or their 
relatives as stipulated in the Declaration of Helsinki. The study was approved by 
the ethics committee of the Hospital District of Northern Savo and the Kuopio 
University Hospital. 
4.2 PATIENT INCLUSION IN SUB-STUDIES  
Sub-study I 
Participants with an MMSE score of ≥18 were included in this sub-study (n=499). 
Sub-study II 
Levels of natriuretic peptides were available and compared in the whole study 
population (n=601), divided into groups by their status of memory illness. The 
prognostic power of BNP for memory illness at fi ve years’ follow-up was analysed 
amongst participants with no memory illness at baseline (n=464). A total of 303 of 
these attended the follow-up visit after fi ve years. Of the 161 participants missing, 
133 died during the study period and 28 either refused to continue the study or 
could not be contacted. 
Sub-study III 
Data on cognitive status were available for the whole study population (n=601), 
and all subjects were included in this sub-study. 
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Sub-study IV 
An evaluation of depressive symptoms was available for 508 persons, who then 
formed the study population. 
4.3 BASELINE DATA 
 A geriatrician and trained nurse interviewed and examined the participants at the 
outpatient clinic of the municipal hospital concerning their medical history and 
use of medications, and recorded the medications they were taking at the time. If 
a participant was unable to visit the study site, the nurse and geriatrician visited 
the home to perform the interview and examination. Interviews were carried out 
with family members and staff in health and social care if the subject was unable 
to provide information, needed health and social services, or lived in an institution. 
The overall physical and neurological status was examined. The study protocol 
included basic laboratory tests and chest x-ray. Patients were also referred for further 
examination and imaging if warranted by their clinical  condition (Rahkonen et al. 
2003). Medical records from the municipal health centre, home nursing service, local 
hospitals and the Kuopio University Hospital were also available. Baseline clinical 
and demographic data was also recorded. Diabetes was defi ned as a diagnosis of 
diabetes in the medical records or a fasting plasma glucose level of 7.0 mmol/l 
or more. Other cardiovascular conditions were recorded from medical records. 
Systolic and diastolic blood pressures were measured twice, and the average of the 
measurements was recorded.  
4.4 LABORATORY MEASURES AND BRAIN IMAGING  
4.4.1 STANDARD LABORATORY MEASURES  
Basic blood count, creatinine, cholesterol profi le, triglycerides and fasting blood 
glucose were measured once at the Kuopio University Hospital after a 12-hour fast 
with no interruption in the medication of the subjects. All serum total cholesterol 
assays were analysed at the Kuopio University Hospital laboratory using standard 
enzymatic techniques. Glomerular fi ltration rate (GFR) was assessed. Creatinine 
clearance was calculated using creatinine, age and body weight according to 
Cockcroft-Gault’s formula (Cockcroft and Gault 1976). The estimation of low-density 
lipoprotein cholesterol was calculated using Friedewald’s formula (Friedewald et 
al. 1972). 
44
 4 Methods 
4.4.2 NATRIURETIC PEPTIDES 
The blood samples for the natriuretic peptide analysis were drawn with other 
blood samples into chilled tubes containing 1.5 mg K2-EDTA per mL of blood 
after the patient had been in a supine position for 30 min at 8 a.m. Whole blood 
was centrifuged and plasma immediately frozen and stored at -70°C. Natriuretic 
peptides were extracted from plasma using Sep-Pak C18 cartridges. BNP was 
extracted from plasma (Vuolteenaho et al. 1992). The radioimmunoassays for ANP 
and NT-pro-ANP  have been described previously (Vuolteenaho et al. 1992) as have 
those for BNP.  The BNP antiserum was raised in a rabbit against carbodiimide 
conjugate of synthetic human BNP-32 (Bachem, Bubendorf, Switzerland) and 
bovine thyroglobulin (Sigma, St. Louis, USA) using methods published previously 
(Vuolteenaho et al. 1985). The sensitivity of the BNP assay was 0.5pmol/L plasma. 
The within- and between-assay coeffi cients of variation in the assay were <10% 
and 15%, respectively. With this method, the following plasma levels (mean ± SD) 
have been detected in healthy adults aged 20–55 years: BNP 6.25 ± 2.12 pmol/L. 
All laboratory data were analysed in random order and blinded to clinical data. 
4.4.3 BRAIN IMAGING 
Brain imaging either by computed tomography (CT) or magnetic resonance imaging 
(MRI) was carried out for all participants with a suspicion of a memory illness but 
no brain imaging in the medical history. The images were routinely analysed by a 
radiologist and an experienced neurologist and geriatrician. 
4.5 MEASUREMENT OF COGNITIVE STATUS 
A history of cognitive decline was obtained by interviewing the subject and relatives 
and other people who knew the subject, and from all the medical records. The 
study nurse used the Finnish version of the MMSE score to screen for cognitive 
dysfunction. Patients were also referred for further examination and imaging if 
warranted by their clinical condition. The behavioural and psychiatric symptoms 
of patients with memory illness were obtained from the relatives or care giving 
personnel whenever possible, as well as from the interview and examination 
(Rahkonen et al. 2003). Memory illness was diagnosed as AD, VaD, DLB or dementia 
due to other medical conditions by an experienced neurologist and geriatrician 
(Raimo Sulkava) according to the DSM-IV criteria and Consensus guidelines for 
the clinical and pathological diagnosis of dementia with Lewy bodies ((McKeith et 
al. 1996). A clinical diagnosis of memory illness was established, whilst stage and 
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type of memory illness were determined in consensus meetings using all available 
data (Rahkonen et al. 2003). Memory illness severity staging was assessed according 
to the DSM-III R criteria, using all data available. 
4.6 MEASUREMENT OF DEPRESSIVE SYMPTOMS STATUS 
Depressive symptoms were assessed with the Zung self-rated depression scale (SDS) 
in Finnish (Zung 1965). Zung SDS was designed for the screening of depressive 
symptoms. The Zung SDS contains 20 items, each with a maximum score of 4. 
Non-depressed individuals typically score less than 40 and scores of 40–80 cover 
various grades of depressive symptoms. The Zung SDS is a valid and sensitive 
method for assessing the severity of depressive symptoms (Biggs et al. 1978). The 
Zung SDS was carried out by a study nurse. 
4.7 FOLLOW-UP 
4.7.1  FOLLOW-UP VISIT AT FIVE YEARS  
A total of 303 (65%) out of 464 participants without diagnosed memory illness 
at baseline visit attended the follow-up visit after fi ve years had passed. Of the 
161 participants missing, 133 died during the study period and 28 either refused 
to continue the study or could not be contacted. During the follow-up visit, the 
diagnostic procedure for memory illness was repeated as described earlier. 
4.7.2 FOLLOW-UP MORTALITY 
Mortality data were obtained from Statistics Finland, which is the national health 
register authority in Finland. There were no losses during follow-up. All deaths 
that occurred between March 1998 and November 2006 were recorded. Lifespan 
was calculated from the date of examination in 1998 to 30 November 2006.The 
causes of death were classifi ed according to the Tenth International Classifi cation 
of Disease (ICD-10), and codes I00–99 were classifi ed as cardiovascular deaths. 
Other deaths were classifi ed as non-cardiovascular. 
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4.8 STATISTICAL ANALYSIS  
4.8.1 GENERAL ASPECTS 
Comparisons of baseline and general characteristics between the groups were 
performed with the aid of the t test for independent samples, the Mann-Whitney 
U test or one-way analysis of variance (ANOVA) as applicable, if the variables were 
continuous variables. The χ2  test was used for categorical data. A logarithmic 
transformation was performed for non-normally distributed variables when 
appropriate and p<0.05 was considered signifi cant. HRs for continuous variables 
were calculated for 1-SD change. 
4.8.2 BNP, MMSE AND MORTALITY 
A Cox proportional hazards model was used with penalized splines. This analysis 
has been described earlier (Greenland 1995). An adjusted model for age and sex was 
created to examine whether the association between mortality and the independent 
variables of BNP and MMSE score changed in a non-linear fashion across the full 
range of these independent parameters. A priori, three degrees of freedom based 
on biological plausibility were selected. When analysis of deviance table with the 
χ2 test was used, non-linear models (penalized splines) did not differ from linear 
models with statistical signifi cance. Therefore, for the rest of the tests, we applied 
linear models.  
To calculate hazard ratio (HR) with 95% CI for BNP and the MMSE score, Cox 
proportional hazards regression models for total and cardiovascular mortality were 
constructed. The proportionality assumption was checked for the main analyses 
based on correlations of survival rankings with Schoenfeld residuals; all covariates 
fulfi lled this criterion. BNP and the MMSE score were tested both as continuous and 
categorical variables.  The pre-specifi ed <24 cut-off point for MMSE score was used, 
which represented approximately the 20th percentile. Similarly, the 80th percentile 
for BNP (79.7 pg/ml) was used as a cut-off point to facilitate comparisons with earlier 
BNP studies. Cardiovascular risk markers and previous illnesses with a signifi cant 
or near-signifi cant (p<.100) stratifi er capacity for mortality and cardiovascular 
mortality, separately, were used as covariates in multivariable Cox proportional 
hazards models. The analyses were further repeated in pre-specifi ed subgroups: 
participants with no diagnosed memory illness (n=454) and participants with no 
previously diagnosed heart failure (n=376). HDL cholesterol and total cholesterol 
were highly collinear and both associated with mortality, but only HDL cholesterol, 
the one with the stronger association, was used in the Cox proportional hazards 
model. 
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4.8.3 BNP, AGE AND MEMORY ILLNESS 
To determine the independent impact that each natriuretic peptide yielded on having 
a memory illness, a multivariable logistic regression analysis was performed. A 
predefi ned interaction term between age and natriuretic peptide was included in 
the analysis. The covariates used in a multivariable regression analysis were: sex, 
age, use of angiotensin-converting enzyme inhibitors or diuretics, systolic arterial 
pressure, and a previous diagnosis of heart failure.   
The study population was divided into three age-groups (tertiles 75–78 years, 
79–82 and 83 and older). The independent predictive value of natriuretic peptides 
on future memory illness in each age-group was studied using a logistic regression 
model. Furthermore, in each age-group an additional multivariable logistic 
regression model was constructed for the variables with a signifi cant association 
to future memory illness in the previous study conducted with the same population 
(Kerola et al. 2010). These variables were: hypertension, BNP, base-line MMSE 
and extent of education. 
4.8.4 BNP AND SEVERITY OF MEMORY ILLNESS 
The LSD post hoc method was used to correct a comparison of BNP levels in each 
memory illness group divided by the severity of the disease. A linear regression 
analysis was used to calculate the impact of age, sex, systolic blood pressure, use 
of diuretics, use of angiotensin-converting enzyme (ACE) inhibitors/angiotensin II 
receptor blockers (ARB), creatinine clearance, and history of heart failure on the 
levels of BNP. All of these factors are known to have an effect on the blood levels 
of BNP. The association between the severity of memory illness and levels of BNP 
resembled an inverse U-shaped curve. Therefore, age-adjusted analysis of covariance 
(ANCOVA) was used to evaluate the relationship between BNP and the severity 
of memory illness. A comparison of the levels of BNP at various stages of memory 
illness in each age tertile was calculated with ANOVA. 
4.8.5 DEPRESSIVE SYMPTOMS, BNP AND MORTALITY 
For the analyses, blood levels of BNP were divided into tertiles, and a categorical 
formulation for BNP was created on this basis: the highest tertile was considered 
BNPhigh for further analysis, while the rest formed the group BNPlow. Risk 
factors with potential stratifi er capacity for mortality and cardiovascular mortality, 
separately, were subjected to univariable Cox proportional hazards models. The 
variables with a signifi cant outcome were included in the fully adjusted models. 
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 4 Methods 
To assess risks related to the various combinations of depressive symptoms (Zung 
SDS ≥40 or <40 – which is a cut-off point often used in the literature), and blood 
levels of BNP (high and low), additional models were used.  
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5 RESULTS 
5.1 MMSE AND MORTALITY (SUB-TUDY I) 
5.1.1 BASELINE DATA 
Subjects with MMSE scores over 17 (n=499) were included in this study. During 
a median follow-up period of 8.4 years (interquartile range [IQR] 8.2–8.6) for 
survivors and 7.9 years (2.7–8.4) for the whole study population, 248 (49.6%) 
participants died, producing an annual mortality rate of 7.9%. Cardiovascular disease 
prevailed as the major cause of mortality, being responsible for 139 (53.9%) deaths. 
Other common causes of death observed were malignancy with 44 (17.1%) cases 
and infection with 22 (8.5%) cases.  
Compared to survivors, the non-survivors were older (81.4 vs 78.5; p<0.001) 
and more likely to have a history of heart failure (28.6% vs 16.2%; p<0.001), atrial 
fi brillation (18.6% vs 11.6%; p=0.030) or stroke (14.7% vs 4.6%; p<0.001). In a 
comparison of individuals who died and those who survived the follow-up period, 
the baseline median (IQR) levels of BNP were higher amongst non-survivors 48.6 
pmol/L (24.0–86.5) than in survivors 27.2 pmol/L (16.2–47.9), respectively (p< 
.001). The initial median of MMSE scores amongst the non-survivors was 26 (24–29) 
and amongst survivors 28 (25–29), (p< .001).   
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Table 3. Hazard ratios for total and cardiovascular mortality during a median follow-up of 7.9 years according 
to baseline BNP and MMSE score (n=499).      
 HR (95% CI) per 1-SD increase in Log variable 
HR (95% CI) for values above the 80th 
percentile for BNP and below the 20th 
percentile for MMSE score 
Total mortality   
Unadjusted model   
    BNP 1.64 (1.44–1.87), p<0.001 2.63 (2.00–3.44), p<0.001 
    MMSE 0.65 (0.58-0.73), p<0.001 2.32 (1.79–3.01), p<0.001 
Age- and sex-adjusted   
model   
    BNP 1.47 (1.30–4.06), p<0.001 2.17 (1.65–2.86), p<0.001 
    MMSE 0.74 (0.65–0.84), p<0.001 1.82 (1.38–2.41), p<0.001 
Multivariable model    
    BNP 1.44 (1.22–1.70), p<0.001 1.85 (1.28–2.66), p=0.001 
    MMSE 0.81 (0.70–0.94), p=0.007 1.40 (1.00–1.97), p=0.048 
Cardiovascular mortality   
Unadjusted model   
    BNP 1.84 (1.56–2.18), p<0.001 3.01 (2.11–4.29), p<0.001 
    MMSE 0.68 (0.58–0.79), p<0.001 2.21 (1.55–3.17), p<0.001 
Age- and sex-adjusted 
model   
    BNP 1.65 (1.38–1.97), p<0.001 2.40 (1.65–3.43), p<0.001 
    MMSE 0.81 (0.68–0.96), p=0.017 1.62 (1.10–2.38), p=0.013 
Multivariable model    
    BNP 1.72 (1.37–2.15), p<0.001 2.18 (1.32–3.56), p=0.002 
    MMSE 0.92 (0.75–1.14), p=0.437 1.11 (0.70–1.76), p=0.659 
In the multivariable model, the parameters included were age, body mass index, New York 
Heart Association class I–II or III–IV, heart failure, systolic blood pressure, hypertension, previous 
myocardial infarction, atrial ﬁ brillation, stroke, diabetes, haemoglobin, high density lipoprotein 
and creatinine clearance, as well as adjustment for MMSE in analysis for BNP and adjustment for 
BNP in analysis for MMSE. Abbreviations: BNP, B-type natriuretic peptide; MMSE, Mini mental state 
examination; HR, Hazard ratio; CI, Conﬁ dence interval 
5.1.2 PREDICTORS OF TOTAL MORTALITY 
Both the MMSE score and BNP as continuous and dichotomous variables were 
signifi cantly linked to mortality when tested separately or in sex- and age-adjusted 
models (Table 3). The age- and sex-adjusted mortality risk increased with the 
increase in the quintile of BNP (p <.001) (Figure 3), with a hazard ratio (HR) of 
2.75 between the lowest and highest quintile. The age- and sex-adjusted risk for 
the MMSE score was elevated with the decrease in the quintile of the MMSE score 
(p <.001) (Figure 3), with an HR of 2.01 between the highest and lowest quintile. 
A further multivariable model was created to investigate the predictive capacity 
of BNP and MMSE score for total and cardiovascular mortality when baseline 
parameters including other co-morbidities and laboratory measures were taken 
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into account. The results of the multivariable model are presented in Table 3. Of the 
parameters used in the multivariable model, age (HR=1.71; 95% confi dence interval 
[CI]=1.42–2.11; p< .001), systolic blood pressure (HR=0.80; 95% CI=0.68–0.98; 
p= 0.029), diabetes (HR=1.65; 95% CI=1.14–2.38; p=0.008), continuous MMSE 
score (HR= 0.81; 95% CI=0.70–0.94; p= .007), and continuous BNP (HR=1.44; 
95% CI=1.22–1.77; p< .001) were independently associated with mortality. 
Of the cardiovascular morbidities, only a history of stroke showed a trend towards 
greater mortality (HR=1.53; 95% CI=0.98–2.36, p=0.070). A history of heart failure, 
myocardial infarction or atrial fi brillation was not independently associated with 
total mortality (p>0.100 for all). BNP was a clear and the MMSE score a borderline 
prognostic factor as dichotomous variables in multiparameter models (Table 3).  
Figure 3. Age- and sex-adjusted Cox proportional hazards survival curves for total and cardiovascular 
mortality divided by B-type natriuretic peptide (BNP) and Mini Mental State Examination Test (MMSE) 
score quintiles (I–V), separately, in the entire study population (n=499). The BNP quintiles were 3.2–17.0, 
17.2–28.0, 28.2–45.3, 46.2–78.8 and 79.7–500 pg/mL. The MMSE score quintiles wre 18 to 23, 24 to 25, 26 
to 27, 28 and 29 to 30.   
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5.1.3 PREDICTORS OF CARDIOVASCULAR MORTALITY 
When tested separately or in an age- and sex-adjusted model, BNP and the 
MMSE score as both continuous and dichotomous variables were associated with 
cardiovascular mortality (Table 3). The age- and sex-adjusted risk of cardiovascular 
mortality was elevated with the increasing quintile of BNP (P < .001), and the 
results are illustrated in Figure 3. HR was 3.29 between the lowest and highest 
quintile. For the MMSE score, a similar model showed no signifi cant connection 
to cardiovascular mortality (p=0.067) (Figure 3), the HR being 1.49.  
A multivariable Cox model was created, with age (HR=1.71; 95% CI=1.42–2.75; 
p< .001), systolic blood pressure (HR=0.74; 95% CI=0.58–0.95; p=0.016), New 
York Heart Association (NYHA) class III–IV vs. I–II (HR=1.64; 95% CI=1.02–2.64; 
p= 0.044), diabetes (HR=1.71; 95% CI= 1.05–2.80; p= 0.033), and BNP (HR= 
1.72; 95% CI=1.37–2.15; p<0.001) associating independently with cardiovascular 
mortality. When tested in the multivariable model (p>0.100 for all), none of 
the cardiovascular conditions with an association to mortality (p<0.100) were 
independent predictors of cardiovascular mortality. The MMSE score showed no 
association with cardiovascular mortality (Table 3) when the known risk-factors 
were fi tted into the same model. We further removed BNP from the model, but no 
material change in the result for MMSE score was found.  
5.2 BNP, AGE AND MEMORY ILLNESS (SUB-STUDY II) 
5.2.1 GENERAL CHARACTERISTICS 
The whole study population (n=601) was included in this study. At fi ve years’ follow-
up, cognitive function was assessed amongst participants without known dementing 
illness at baseline (n=464). A total of 303 of them attended the follow-up visit after 
5 years. The general characteristics of the study population divided by their status 
of memory illness are given in Table 4. The participants were further divided into 
four groups according to diagnosis of memory illness. 
AD was the largest group of memory illness, affecting a total of 64 participants, 
while VaD was diagnosed in 32 and DLB in 30 participants. The total size of control 
group was 464 participants. The participants in the groups with a diagnosed memory 
illness were slightly older than those with no diagnosed memory illness.  Females 
formed the majority in all four groups. The participants in the groups with a 
diagnosed memory illness had lower systolic and diastolic blood pressure as well 
as lower high density lipoprotein cholesterol levels when compared to participants 
not suffering from memory illness. BMI showed a tendency towards being lower in 
those with a diagnosed memory illness, especially in the case of DLB. Participants 
with a diagnosed memory illness had a relatively low median MMSE score (14–15) 
in all diagnostic groups. A history of heart failure was also most common amongst 
participants with diagnosed VaD.   
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Table 4. General characteristics of participants divided by their status of memory illness. 
 No memory illness (n=464) 
Memory illness 
(n=137) p-value 
Age, mean (SD) 80.0 (4.3) 83.2 (4.8) <0.001 
Female, n (%) 336 (72.4) 107 (78.1) 0.224 
Mean systolic blood pressure, mean (SD) 
mm Hg 153.1 (24.2) 137.8 (22.1) <0.001 
Mean diastolic blood pressure, mean (SD) 
mm Hg 76.6 (10.8) 72.4 (11.0) <0.001 
BMI, mean (SD) 26.5 (4.5) 24.2 (4.0) <0.001 
Zung, median (IQR) 39 (33,45) 42 (36,49) 0.005 
MMSE median (IQR) 27 (24,29) 14 (6,19) <0.001 
Previous illnesses    
    Diabetes, n (%) 94 (20.3) 23 (16.8) 0.393 
    Myocardial infarction, n (%) 149 (32.1) 50 (36.5) 0.353 
    Heart failure, n (%) 113 (24.4) 49 (35.8) 0.011 
    Atrial ﬁ brillation, n (%) 70 (15.1) 26 (19.0) 0.289 
    Peripheral vascular disease, n (%) 50 (10.8) 12 (8.8) 0.631 
    TIA, n (%) 66 (14.2) 26 (19.0) 0.179 
    Stroke, n (%) 47 (10.1) 25 (18.2) 0.016 
Medication    
    Beta-blockers 205 (44.2) 42 (30.6) 0.006 
    ACE inhibitor/ARBs 96 (20.7) 17 (12.4) 0.034 
    Aspirin 179 (38.6) 41 (29.9) 0.070 
    Diuretics 161 (34.7) 60 (43.8) 0.056 
    Statins, n (%) 23 (5.0) 0 (0) 0.004 
    Calcium channel blocker, n (%) 83 (17.9) 9 (6.6) 0.001 
    Oral diabetes medication, n (%) 34 (7.3) 8 (5.8) 0.703 
    Insulin, n (%) 17 (3.7) 2 (14.6) 0.270 
History of smoking, n (%) 121 (26.1) 24 (17.5) 0.280 
Laboratory count    
    Total cholesterol, mean (SD) mmol/l 5.7 (1.2) 5.2 (1.1) <0.001 
    HDL cholesterol, mean (SD) mmol/l 1.5 (0.4) 1.3 (0.3) <0.001 
    Haemoglobin  133.4 (12.7) 129.73 (14.9) 0.005 
    Creatinine clearance, mean (SD)              
    ml/min   52.9 (15.4) 42.6 (13.9) <0.001 
Abbreviations: SD, standard deviation; MMSE, Mini mental state examination score; IQR, 
interquartile range; BMI, body mass index; ACE, angiotensin converting enzyme; ARB, angiotensin 
receptor blocker; HDL, high density lipoprotein; TIA. transient ischemic attack 
5.2.2 NATRIURETIC PEPTIDES AND MEMORY ILLNESS 
Levels of BNP increased with age in participants without known memory illness 
(p<0.001), but not amongst those with a diagnosed memory illness (p=0.892) 
(Figure 4). The levels of natriuretic peptides were similar in the four groups by 
memory illness (Table 5).  A highly signifi cant (p=0.004) interaction was observed 
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between BNP and age in the logistic regression model where the presence of a 
memory illness was the dependent factor. Therefore, the study population was 
divided into age group tertiles for further analysis: 75 to 78 years (n=235), 79 to 
82 years (n=175) and 83 years or older (n=191). In the youngest tertile, there was a 
signifi cant positive association between BNP levels and diagnosed memory illness in 
the adjusted logistic regression model (Table 6). In the middle tertile, no connection 
between BNP and memory illness was found, whilst in the oldest tertile an opposite 
trend was observed: BNP levels were higher amongst those with no diagnosed 
memory illness (p=0.05) in the regression model. When tested in the whole study 
population or the various age tertiles, NT-ANP and ANP showed no association 
with the presence of memory illness. 
 Figure 4. Mean levels of BNP (with SD error bars) for groups with and without memory illness by age 
tertile. The p-values were calculated with analysis of variance. 
 Elevated BNP is known to associate with increased mortality. In order to take 
the potential distortion of increased mortality amongst those with elevated levels of 
BNP into account, we analysed the association between BNP and memory illness in 
various age tertiles after excluding participants who died within 12 months after the 
beginning of follow-up. The result remained the same after the exclusion, as BNP 
levels increased with age in participants with normal cognition (p<0.001), but not 
amongst those with a diagnosed memory illness (p=0.839).   
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 Table 5. Blood levels of natriuretic peptides by memory illness 
Natriuretic peptide Controls AD VaD DLB p-value 
NT-ANP, mean (SD) pmol/l 917.1 (572.0) 953.7 (596.9) 1060.2 (799.4) 993.9 (546.5) 0.634 
ANP, mean (SD) pg/ml 86.3 (57.9) 88.4 (73.0) 97.2 (73.5) 92.2 (55.6) 0.791 
BNP, mean (SD) pg/ml 55.2 (66.0) 58.3 (65.5) 65.9 (98.0) 47.4 (37.4) 0.898 
Abbreviations: AD = Alzheimer`s disease, ANP = A-type natriuretic peptide, BNP = B-type 
natriuretic peptide, DLB = dementia with Lewy bodies, NT-ANP = N-terminal fragment of ANP, SD 
= standard deviation, VaD = vascular dementia;  
Table 6. Cross-sectional multivariable logistic regression analysis presenting SD-adjusted odds ratios of 
natriuretic peptides for their association with a memory illness in each age tertile 
 OR 95% CI p-value 
BNP    
    75–78 years  1.44  1.01–2.07 0.047 
    79–82 years  1.16 0.76–1.78 0.486 
    83–96 years  0.57 0.32–1.00 0.050 
ANP    
    75–78 years  1.24 0.82–1.88 0.309 
    79–82 years  1.10 0.70–1.71 0.682 
    83–96 years  0.65 0.40–1.03 0.064 
NT-ANP    
    75–78 years  1.00 0.65–1.61 0.941 
    79–82 years  1.06 0.71–1.65 0.734 
    83–96 years  0.73 0.50–1.07 0.120 
The following covariates were included in the multivariable logistic regression model: age, sex, 
use of ACE inhibitor, use of diuretics, history of heart failure, mean systolic blood pressure. 
Abbreviations: ACE = angiotensin converting enzyme, CI = conﬁ dence interval, OR = odds ratio           
 
We repeated the adjusted logistic regression analysis regarding the association 
between BNP and memory illness as described above. The link between levels of 
BNP and memory illness remained on the same level after the exclusion, with hazard 
ratios (HR) of 1.54 in the youngest tertile (95% confi dence interval [CI] 1.03–2.29; 
p=0.035), 1.13 in the middle tertile (95 % CI 0.72–1.75; p=0.607) and 0.78 in the 
oldest tertile (95% CI 0.59–1.08; p=0.133). 
We further analysed the impact of BNP on memory illness during the follow-
up. A total of 60 out of 464 participants free of memory illness at baseline were 
diagnosed with memory illness at the follow-up visit. The same diagnostic criteria 
for memory illness were used during the follow-up visit as during the baseline visit. 
The levels of BNP at baseline for the age tertiles in groups divided by their status 
of memory illness at the follow-up visit are presented in Figure 5. 
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Figure 5. Mean levels of BNP (with SD error bars) amongst the participants at baseline for groups with and 
without memory illness during the follow-up visit. The p-values were calculated with analysis of variance. 
The association was present only in the youngest age group (RR 1.83; 95% CI 
1.06–3.16; p=0.027), whilst in the middle-group (79–82 years) there was a trend 
towards higher BNP levels amongst those with memory illness during the follow-
up (RR 1.44, 95% CI 0.85–2.43; p=0.17). In the oldest group (83 years and older), 
the association was no longer present (RR 1.11, 95% CI 0.60–2.06; p=0.75). In the 
multivariable regression analysis including other variables with signifi cant predictive 
capacity for memory illness in a previous study conducted with the same study 
population (Kerola et al. 2010) (length of education, age, hypertension), the results 
were parallel (the youngest group: RR 1.89, 95% CI 1.07–3.34, p=0.028; the middle 
group: RR 1.81, 95% CI 0.97–3.39; p=0.062; the oldest group: RR 0.983, 95% CI 
0.48–2.01 p=0.966). The prognostic power of NT-ANP and ANP in similar settings 
was clearly inferior to BNP. For ANP, RR in the youngest tertile was 1.18 (95% CI 
0.71–1.97, p=0.523); in the middle tertile 1.55 (95% CI 0.88–2.73, p=0.126) and in 
the oldest tertile 0.76 (CI 0.38–1.53, p=0.441). For NT-ANP, RR in the youngest 
tertile was 1.23 (95% CI 0.76–1.99, p=0.388); in the middle tertile (95% CI 0.83–
2.82, p=0.171); and in the oldest tertile 0.56 (95% CI 0.36–1.69, p=0.304). 
5.3 BNP AND SEVERITY OF MEMORY ILLNESS (SUB-STUDY III) 
5.3.1 GENERAL CHARACTERISTICS 
Data on cognitive status was available for the whole study population (n=601), 
and all subjects were included. Those with disease-causing cognitive decline were 
older and had lower body mass index than their counterparts with no diagnosed 
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memory illness. Also amongst participants with disease-causing cognitive decline, 
both diastolic and systolic blood pressure was lower, creatinine clearance was lower, 
and the use of antihypertensive medication less common than amongst individuals 
with no diagnosed memory illness.  
We investigated the association of variables with levels of BNP in univariable 
linear regression models. Age, diastolic blood pressure, creatinine clearance, the use 
of diuretics, use of ACE inhibitors/ARBs, history of stroke and a previous history 
of heart failure had a signifi cant association with the level of BNP, whilst systolic 
blood pressure and sex were not signifi cantly connected to BNP (Table 7). 
The association between the severity of memory illness and levels of BNP 
resembled an inverse U-shaped curve (Figure 6). The levels of dementing illness 
were assessed in accordance with DSM-III-R criteria. The highest levels of BNP 
were observed amongst those with a mild memory illness. In severely affected 
participants, the levels of BNP were even lower than in their counterparts without 
known dementing illness. (ANOVA p=0.077). In the post hoc LSD analysis, the 
levels of BNP were signifi cantly higher in mild memory illness compared to severe 
memory illness (p=0.012). In the same analysis, the levels of BNP showed a tendency 
towards being higher in participants with mild memory illness than in participants 
without known dementing illness (p=0.050). Other comparisons of the levels of 
BNP between the groups were not statistically signifi cant. 
Table 7. Associations of clinical variables with blood levels of BNP, with standard error (SE) 
 Beta (SE) p-value    
Sex -0.005 (0.035) 0.901    
Age 0.229 (0.003) <0.001    
Diastolic blood pressure -0.167 (0.001) <0.001    
Systolic blood pressure -0.056 (0.001) 0.180    
Creatinine clearance -0.262 (0.001) <0.001    
Use of ACE inhibitors/ARBs 0.172 (0.039) <0.001    
Use of diuretics 0.130 (0.032) 0.002    
Atrial ﬁ brillation 0.303 (0.041) <0.001    
History of heart failure 0.318 (0.033) <0.001    
History of stroke 0.134 (0.048) 0.001    
Abbreviations: BNP, B-type natriuretic peptide; ACE, angiotensin converting enzyme; ARB, 
angiotensin II receptor blocker 
In the age-adjusted analysis of covariance (ANCOVA), the association between 
the level of memory illness and the levels of BNP was signifi cant (p=0.02). In a 
multivariable ANCOVA model where factors known to have a connection with levels 
of BNP were included as covariates, association between BNP and stage of memory 
illness was no longer present (p=0.254).  
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Figure 6. Blood levels of BNP (with SD error bars) in groups divided by status of memory illness. P-value 
(0.077) for levels of BNP was calculated with ANOVA.  
 We divided the study population into age group tertiles for further analysis: 
75–78 years (n=235), 79–82 years (n=175) and 83 years or older (n=191). The 
levels of BNP for each age tertile divided by their status of dementing illness are 
presented in Figure 7. In the youngest and middle tertile, the levels of BNP resembled 
an inverse U-shaped curve, being highest in the groups with mild memory illness 
(ANOVA p=0.494 and p=0.219, respectively). This inverse U-shape tendency was 
lost in the oldest age tertile where the highest levels of BNP were detected amongst 
the participants without known dementing illness (p=0.047).  
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Figure 7. Blood levels of BNP (pg/ml) in age tertiles divided by their status of memory illness 
5.4 DEPRESSIVE SYMPTOMS, BNP AND MORTALITY 
 (SUB-STUDY IV) 
5.4.1 BASELINE CHARACTERISTICS 
The Zung SDS was available for 508 participants and they formed the study 
population. Also participants with diagnosed memory illness were included in this 
study. The cut-off point for depressive symptoms was 40. Baseline characteristics 
are described briefl y. Survival data were available for all participants. The follow-up 
time lasted up to 106 months (median 84 months, interquartile range 36–99). In 
the depressive symptoms group, 146 (59.8%) persons died during the follow-up; 
85 (34.8%) fatalities were considered cardiovascular deaths. In the non-depressive-
symptoms group, the total mortality rate was 120 (45.4%) and cardiovascular 
mortality 61 (23.1%). Individuals with depressive symptoms were slightly older 
than their counterparts (81.0 years vs. 79.5 years; p<0.001). A history of heart failure 
and NYHA class III–IV were more common amongst individuals with depressive 
symptoms (p<0.001 for both). 
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5.4.2 PREDICTORS OF TOTAL MORTALITY 
BNP was a signifi cant predictor of total mortality in an age- and sex-adjusted (HR 
1.37; 95% CI 1.22–1.53; p<0.001). BNP remained a signifi cant predictor of total 
mortality in a multivariable Cox regression model, even when depressive symptoms 
were included as a covariate (HR 1.44; 95% CI 1.22–1.69; p<0.001). Depressive 
symptoms had signifi cant prognostic value for total mortality in a univariable 
analysis (HR 1.60; 95% CI 1.26-2.04; p<0.001) as well as in an age- and sex-adjusted 
model (HR 1.39; 95% CI 1.08–1.78;p=0.009). However, depressive symptoms lost 
their signifi cance as a predictor of total mortality in a multivariable model including 
BNP (HR 1.21; 95% CI 0.91–1.63; p=0.166). The impact of depressive symptoms 
on total mortality in a fully adjusted model is illustrated in Figure 8. 
The relative importance of BNP and depressive symptoms in the prediction of 
mortality is illustrated in Figure 8. The unadjusted, age- and sex-adjusted and fully 
adjusted HRs for mortality in the groups divided by the combinatory variable of 
depressive symptoms and BNP levels are presented in Table 8.  
5.4.3 PREDICTORS OF CARDIOVASCULAR MORTALITY 
In a multivariable model, when depressive symptoms were also included as a 
covariate, continuous BNP had signifi cant prognostic value for cardiovascular 
mortality (HR 1.79; 95% CI 1.44–2.22; p<0.001). Depressive symptoms had 
signifi cant prognostic value for cardiovascular mortality in an unadjusted model 
(HR 1.81; 95% CI 1.30-2.52; p<0.001) as well as in an age- and sex-adjusted model 
(HR 1.52, CI 1.08–2.13; p=0.015). As for total mortality, depressive symptoms did 
not have signifi cant prognostic value on cardiovascular mortality in a fully adjusted 
model (HR 1.27, 95% CI 0.88–1.85; p=0.203). 
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Table 8. Hazard ratios (HR) and 95% conﬁ dence intervals (CI) for groups divided by their levels of BNP 
and status of depressive symptoms against the group “BNPlow without depressive symptoms” 
 Total mortality HR (95% CI), p-value 
Cardiovascular mortality 
HR (95% CI), p-value 
BNPlow with depressive symptoms   
    Unadjusted 1.49 (1.08–2.08), p=0.017 1.67 (1.04–2.69), p=0.035 
    Age- and sex-adjusted 1.42 (1.02–1.98), p=0.036 1.58 (0.98–2.55), p=0.061 
    Multivariable 1.29 (0.88–1.88), p=0.191 1.24 (0.71–2.17), p=0.446 
BNPhigh without depressive symptoms  
    Unadjusted 2.17 (1.50–3.15), p<0.001 2.91 (1.75–4.84), p<0.001 
    Age- and sex-adjusted 2.04 (1.71–2.94), p<0.001 2.71 (1.63–4.50), p<0.001 
    Multivariable 1.90 (1.25–2.88), p=0.003 2.77 (1.56–4.90), p<0.001 
BNPhigh with depressive symptoms   
    Unadjusted 3.17 (2.28–4.40), p<0.001 4.51 (2.87–7.07), p<0.001 
    Age- and sex-adjusted 2.41 (1.71–3.40), p<0.001 3.26 (2.04–5.22), p<0.001 
    Multivariable 2.12 (1.39–3.22), p<0.001 2.67 (1.50–4.76), p=0.001 
In the multivariable model for total mortality, the parameters included were age, 
systolic blood pressure, creatinine clearance, haemoglobin, body mass index, history of 
myocardial infarction, history of stroke, atrial ﬁ brillation, heart failure, New York Heart 
Association class I–II or III–IV, and high-density lipoprotein 
 The impact of depressive symptoms on cardiovascular mortality in a fully adjusted 
model is illustrated in Figure 8. The relative importance of BNP and depressive 
symptoms on cardiovascular mortality are depicted in Figure 8. Unadjusted, age- 
and sex-adjusted as well as fully adjusted HRs for cardiovascular mortality in groups 
divided by variable combining depressive symptoms and BNP are presented in 
Table 8. 
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5 Results 
Figure 8. The multivariable Cox regression model for total and cardiovascular mortality; groups divided 
by levels of BNP and status of depressive symptoms. In the multivariable model for total mortality, the 
parameters included were age, systolic blood pressure, creatinine clearance, haemoglobin, body mass index, 
history of myocardial infarction, history of stroke, atrial ﬁ brillation, heart failure, New York Heart Association 
class I–II or III–IV, and high-density lipoprotein. In the multivariable model for cardiovascular mortality, 
the parameters included were age, systolic blood pressure, creatinine clearance, history of myocardial 
infarction, history of stroke, atrial ﬁ brillation, heart failure, diabetes, New York Heart Association class I–II 
or III–IV, and high-density lipoprotein.
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6 DISCUSSION 
6.1 MORTALITY 
In the general elderly population, BNP has shown prognostic value for mortality in 
earlier studies (Kistorp et al. 2005, Wallen et al. 1997). In a large home-dwelling 
population (n= 3,123, mean age 59±15 years), BNP predicted cardiovascular and 
all-cause mortality (Tsuchida and Tanabe 2008). Extensive mortality data enabled 
us to examine total mortality and cardiovascular mortality separately. Our main 
fi ndings were that MMSE was an independent predictor of total mortality but had 
no independent value as a predictor of cardiovascular mortality. Secondly, while 
depressive symptoms refl ected the susceptibility to all-cause and cardiovascular 
mortality, they had no independent predictive power in an aged general population 
when cardiovascular illnesses and risk markers were taken into account. In the 
analysis where risk markers for mortality were investigated (sub-studies I and IV), 
BNP remained a strong predictor of total and cardiovascular mortality, regardless 
of MMSE score or depressive symptoms status. 
Cardiovascular diseases such as diastolic heart failure and asymptomatic 
heart failure, which affect the levels of BNP, are common in the elderly (Redfi eld 
et al. 2003). Other morbidities infl uencing the levels of BNP are, for example, 
hypertension, previous myocardial infarction and atrial fi brillation (Vuolteenaho, 
et al. 2005). The commonness of cardiovascular disease amongst older people is 
likely to explain the previous fi ndings that BNP has showed excellent performance 
as a predictor of mortality. Our data enabled us to use the cardiovascular conditions 
mentioned above as covariates in a multivariable analysis. In all the models applied, 
BNP remained a signifi cant predictor of mortality. It is also notable that the median 
BNP level in our study population was low in comparison to those seen in patients 
with clinical heart failure. This fi nding suggests that even a modest increase in the 
level of BNP has predictive value for mortality. Other biomarkers besides natriuretic 
peptides have also been tested as prognostic tools. In one study, C-reactive protein 
(CRP) – a marker of infl ammation – was found to be associated with cardiovascular 
risk factors in the elderly, but the predictive capacity of CRP with regard to mortality 
was present only in a 75-year old cohort and was lost in older cohorts (Strandberg and 
Tilvis 2000). When the prognostic performance of NT-proBNP was compared with 
that of CRP, NT-proBNP outperformed CRP as a prognostic tool for cardiovascular 
events and death in a population aged 50–89 years (Kistorp et al. 2005).  
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Previous studies have shown that traditional cardiovascular risk markers such as 
hypertension, hyperlipidemia and obesity are known to lose much if not all of their 
prognostic power when measured in the elderly (Oates et al. 2007, Takata et al. 2007). 
In concordance with earlier studies, low blood pressure and low cholesterol had an 
inverse association with mortality in the present study. In older populations, several 
conditions are frequently found which may attenuate systemic blood pressure. Such 
conditions are, for example, dehydration, heart failure, atrial fi brillation and aortic 
stenosis. This cardiovascular morbidity may impair the prognostic value of high 
blood pressure amongst the aged.  The cardiovascular diseases mentioned above 
may place the cardiovascular system under stress and increase BNP levels without 
elevated – or even with low – blood pressure. It has been suggested that an excess 
risk of cardiovascular events and death is apparent at natriuretic peptide levels well 
below the current thresholds used to diagnose heart failure (Wang et al. 2004a).  
In the present study, diabetes and a high NYHA class were associated with poor 
outcome, which was in concordance with earlier studies. (Franco et al. 2007, Ahmed 
et al. 2006). As was expected on the basis of earlier studies on the study population, 
quantitative measures of disease – such as MMSE score – proved to predict outcome 
better than the mere existence of a condition (Fried et al. 1998). Depressive symptoms 
formed an exception in this regard as they lost their signifi cance as a predictor of 
mortality in a multivariable model, both as a dichotomous and a continuous variable. 
6.1.1 MMSE AND MORTALITY 
This is the fi rst study to examine the predictive capacity of increased haemodynamic 
load, with BNP as its biomarker, and the MMSE score simultaneously in combination 
with established cardiovascular risk markers. The connection between cognitive 
decline and cardiovascular morbidity in the older population has been addressed 
in previous studies (Buerger et al. 2009, Iadecola and Davisson 2008, Kerola et 
al. 2010).  
In the present study, the MMSE score was a signifi cant predictor of all-cause 
mortality in all models, although its independent value was only moderate in a 
multivariable model. There are previous studies investigating the prognostic value 
of cognitive impairment on mortality. In a study where the prognostic value of 
cognitive impairment and a decline in cognitive function during a 3-year follow-
up was examined (n=1997), it was found that both mild (defi ned as MMSE score 
18–23) and severe cognitive impairment (MMSE score 0–17) were predictors of 
mortality amongst individuals aged under 80 years (Bassuk et al. 2000).  In a 
Finnish study performed amongst home-dwelling patients with cardiovascular 
disease and aged 75 and older (n=398), a low MMSE score was found to be a 
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strong predictor of mortality as persons with an MMSE score of 18–23 had a 2.4-
fold risk of death compared to those with an MMSE score of 27–30 (Strandberg 
et al. 2009). One study in which the Short Portable Mental Status Questionnaire 
(SPMSQ) was used as a measure of cognition (n=3957) found that moderate and 
severe cognitive impairment, but not mild cognitive impairment, were predictors 
of mortality during 5 to 7 years of follow-up (Stump et al. 2001). The impact of 
cognitive impairment on mortality has also been studied recently, and there are a 
few studies published after ours with results resembling ours. One recent study was 
in concordance with our study and showed that both moderate and mild cognitive 
dysfunction were signifi cant predictors of mortality in the elderly. In the same 
study, the MMSE domains of orientation to time and attention were independently 
associated with an increased risk of mortality (Park et al. 2013). One interesting 
fi nding was recently published, showing that, in an elderly population, preclinical 
AD, defi ned by changes in amyloid and neuronal injury markers in cerebrospinal 
fl uid as well as cognitive changes, predicts mortality. In addition to predicting future 
cognitive decline, preclinical AD was also associated with increased mortality during 
5-years of follow-up (Vos et al. 2013). 
 We further performed a subanalysis to avoid the strong prognostic implications 
of a diagnosis of memory illness, and individuals with a diagnosed memory 
illness (n=45) were excluded (all with MMSE ≥18). However, it must be taken 
into consideration that although  those with diagnosed memory illness were 
excluded, it is possible that some participants had undiagnosed memory illness, 
since diagnostic tools at the time of the baseline visit were not as good as they are 
today. After excluding participants with an established compromised prognosis, the 
prognostic value of the MMSE score was somewhat attenuated but not abolished. 
This observation suggests that other pathways besides memory illness may convey 
the prognostic value of the MMSE score. The reasons for this are speculative, but 
these additional mechanisms may be related to, for example, behavioural aspects, 
such as compliance with medication as well as to life-style and activity level in 
addition to nutrition. Memory illnesses were not separately recorded as causes of 
death in this study. It is possible that some participants with attenuated cognitive 
function at baseline developed a memory disease during the follow–up, and cause 
of death eventually was memory disease. 
6.1.2 THE MMSE SCORE AND CARDIOVASCULAR MORTALITY 
In previous studies, natriuretic peptides as biomarkers of cardiovascular stress have 
been connected to memory illness as well as future cognitive decline (Buerger et 
al. 2009, Gunstad et al. 2006, Buerger et al. 2011). One study showed a positive 
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correlation between MMSE score, plasma BNP and advanced age (Feola et al. 2007). 
In a recent study with the same population as the present study, BNP was also 
reported to associate with declining cognitive function and future dementia in a 
population free of dementing illness at baseline (Kerola et al. 2010). The failure of 
traditional cardiovascular risk markers for the elderly and accumulating evidence of 
the association between cardiovascular burden and cognitive dysfunction have led 
to the hypothesis that cognitive impairment and a decreased MMSE score may hold 
additional predictive value for cardiovascular mortality (Strandberg et al. 2009). 
The fi nding of the present study was that a moderately attenuated MMSE score 
– though associated with cardiovascular mortality separately or in an age- and 
sex-adjusted model – has no independent prognostic capacity together with known 
cardiovascular risk markers. This fi nding suggests that, in our study population, the 
MMSE score is closely linked to cardiovascular stress when it comes to predicting 
cardiovascular mortality. 
6.2 DEPRESSIVE SYMPTOMS AND MORTALITY 
6.2.1  DEPRESSIVE SYMPTOMS AND TOTAL MORTALITY 
In an elderly population, depressive symptoms are common and their prevalence 
increases with age (Arve et al. 2012). Studies have shown that, in an elderly 
population, depressive symptoms are associated with increased mortality (Schulz 
et al. 2000, Wada et al. 2011). Studies investigating the independent predictive 
value for mortality posed by natriuretic peptides and depression when studied 
simultaneously have been very few. In one study, the fi nding was that depression 
and NT-proBNP are independent and additive predictors of cardiovascular and all-
cause mortality in patients with diagnosed heart failure (n=208) during a median 
follow-up time of 10 years (van den Broek et al. 2011).  
 In our study population, depressive symptoms were associated with mortality 
in the univariate and the age- and sex-adjusted models. After adjustment for known 
cardiovascular illnesses and risk factors, this association was lost. Participants 
with depressive symptoms were more prone to several conditions with a known 
poor prognosis, and BNP levels were signifi cantly higher amongst participants 
with depressive symptoms. It is notable that heart failure and peripheral vascular 
disease were twice as common amongst the participants with depressive symptoms 
when compared to their non-depressed counterparts. Previously, depression has 
been linked to excess mortality. The fi nding of the present study suggests that 
depression-related excess mortality is closely linked to other morbidity, particularly 
cardiovascular disease. 
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6.2.2 DEPRESSIVE SYMPTOMS, CARDIOVASCULAR MORBIDITY AND   
 MORTALITY 
It is recognised that depressive symptoms are common and associated with poor 
prognosis in patients with heart failure. (Sherwood et al. 2007, Lesman-Leegte et 
al. 2009, Murberg and Furze 2004, Vaccarino et al. 2001). There is also convincing 
evidence from a meta-analysis (Van der Kooy et al. 2007) and a large study 
population of 43,093 individuals in a cross-sectional study (Niranjan et al. 2012) 
that depression is a predictor of future heart disease.   
Despite the decreasing stroke mortality rates of recent years due to improved 
treatment, stroke still remains as a major cause of mortality amongst older people 
(Zhang et al. 2012). It is well known that post-stroke depression is common amongst 
stroke survivors (Hackett and Anderson 2005, Kauhanen et al. 1999) and that 
depressive symptoms increase the risk of mortality amongst stroke patients (Ellis 
et al. 2010). It has been proposed, however, that depression may be a risk factor 
for stroke, particularly in the older population (Hakim 2011).  
We found that depressive symptoms did not signifi cantly augment the predictive 
power of BNP.  In the present study, depressive symptoms were only a modulating 
factor in the prognosis, whereas BNP remained a strong predictor of mortality in 
all the models. The mechanisms underlying the association between depressive 
symptoms and cardiovascular mortality are not yet fully understood. Infl ammatory 
mechanisms have been proposed to link depressive symptoms to heart failure 
(Ferketich et al. 2005). In one study (n=300, mean age 65±12), BNP and anti-
infl ammatory cytokine interleukin-10 levels predicted an adverse outcome for heart 
failure patients with depressive symptoms (Zung SDS 40 or more) (Parissis et al. 
2009). In addition, several other mechanisms – such as impaired immune function 
as well as dysfunction of the autonomic nervous system, endothelial function and 
hypothalamic-pituitary-adrenocortical axis function – link depressive symptoms to 
cardiovascular disease (Grippo and Johnson 2002, Moretti et al. 2011). The evidence 
linking depression and stroke is even less well understood, but infl ammatory 
mechanisms as well as haemodynamic and structural changes have been proposed 
to link depression and brain vascular disease (Hakim 2011).  
Behavioural changes may also partially explain the association between depressive 
symptoms and increased cardiovascular morbidity. Depressed individuals have 
higher rates of non-compliance with medication and are less likely to improve 
their physical activity or stop smoking than non-depressed people (van der Wal 
et al. 2006, van der Wal et al. 2005). Somatic medical conditions are common 
amongst older people, and somatic diseases are linked to an increased prevalence 
of depressive symptoms amongst the aged (Krishnan et al. 2002). In the present 
study, BNP was clearly superior to depressive symptoms as a predictor of mortality, 
and depressive symptoms were only a modulating factor in the prognosis. 
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6.3 COGNITION 
Our study showed two novel fi ndings on the relationship between BNP and 
cognition. Firstly, the association of BNP with memory illness changes with aging 
amongst older individuals. In the youngest age tertile (75–78 years), elevated BNP 
was connected to impaired cognition, while the oldest participants (83–96 years) 
had lower BNP levels in conjunction with memory illness. In parallel, amongst the 
participants free of memory illness at baseline, the previously reported association 
of BNP with memory illness during the follow-up was only present in the age group 
of 75–78 years. ANP and NT-ANP showed no signifi cant association with memory 
illness. We also tested the association between BNP and various stages of severity 
of memory illness, as information on this association has been lacking. Our main 
fi nding was that the association of memory illness and BNP is dependent on the 
severity of memory illness and resembles an inverse U-shaped curve where highest 
levels of BNP were found amongst those with mild memory illness. 
6.3.1 COMPARISON OF NATRIURETIC PEPTIDES 
We compared the connection of the levels of BNP, ANP and NT-ANP with memory 
illness. The results showed the superiority of BNP in this regard in comparison to 
the other natriuretic peptides investigated. Before the present study, this comparison 
between BNP and ANP has been made in a very limited study population: in a 
Japanese study with a small group of patients with memory illness (n=42) but no 
cardiovascular disease, BNP levels were signifi cantly linked to cognitive function, 
whereas the levels of ANP were not (Naito et al. 2009). The reasons for the superiority 
of BNP are speculative. The effects of ANP and BNP are mediated by the same 
receptor, natriuretic peptide receptor-A (NPR-A) (Potter et al. 2009), and the effects 
are therefore qualitatively similar. They are both natural antagonists of the renin-
angiotensin-aldosterone system, and enhance the excretion of water and salts to 
urine, resulting in a reduced fi lling of the heart and lowered blood pressure. They 
also inhibit the sympathetic nervous system. Age and gender have equal effects on 
the plasma levels of all these natriuretic peptides (Alehagen et al. 2007 , Bhandari 
et al. 2011, Loke et al. 2003).   
Secretion of ANP and NT-proANP takes place mainly in the atria of the heart, 
whereas BNP is secreted from both the atria and the ventricles in the healthy state 
(Ruskoaho 2003). Comparisons between ANP and BNP as diagnostic markers 
in heart failure have been made, and the results support the superiority of BNP 
(Abassi et al. 2004). In a study on elderly patients with heart failure (n=415, aged 
65-82 years), BNP was superior to ANP in evaluating information for identifying 
patients with impaired systolic function and diastolic dysfunction as well as for 
assessing the risk of cardiac death (Alehagen et al. 2007). Comparisons between 
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BNP and NT-proANP have also been made, with diverse results. Generally, BNP 
has also been slightly superior to NT-proANP as a diagnostic and prognostic marker 
(Vasan et al. 2002, McDonagh et al. 1998, Yamamoto et al. 1996), although some 
studies have found their performance equal or that of NT-proANP even better 
(Seronde et al. 2013, Alehagen et al. 2007, Yamamoto et al. 1996, Ala-Kopsala et 
al. 2005). The superior performance of BNP in the present study may be explained 
by the differences in clearance between the natriuretic peptides. Also, the more 
direct association of the secretion of BNP with changes in cardiac gene expression 
as opposed to ANP  (Ruskoaho 2003) is one possible explanation. Due to these 
reasons, BNP may better refl ect the burden caused by haemodynamic load on the 
cerebral vasculature.  
6.3.2 AGE, BNP AND COGNITION 
Previous studies have demonstrated an association between natriuretic peptides and 
cognitive decline. However, the study populations in previous studies investigating 
this association have been younger than in the present study. It was known that 
cardiovascular risk factors and heart failure are associated with cognitive decline. 
This fact raised the question as to whether increased haemodynamic load and BNP 
as a biomarker of cardiovascular stress are associated with cognition. The fi rst study 
to investigate the association between BNP and cognition was published in 2006, 
demonstrating that levels of BNP were independently connected with cognitive 
dysfunction (Gunstad et al. 2006) in small group of patients with cardiovascular 
disease (n=56, mean age 70 ± 8 years). A cross-sectional study found that plasma 
BNP levels were correlated with cognitive performance (Feola et al. 2007) in heart 
failure patients (n=60, mean age 65.5 years). One study investigated the relationship 
between BNP and two major subtypes of memory illnesses, AD and VaD.  BNP was 
elevated amongst patients with subcortical VaD (mean age 69 years, n=15) but not 
amongst age-matched controls (mean age 69 years, n=19) or patients with AD (mean 
age 71 years, n=19); the fi nding suggested a larger vascular burden in subcortical 
VaD than in the other groups (Kondziella et al. 2009). However, elevated levels 
of natriuretic peptides have also been found in patients with AD. In one study, 
increased levels of NT-proANP were detected in patients with diagnosed AD (mean 
age 73.9, n=94) when compared to healthy controls (mean age 65.5, n=53) (Buerger 
et al. 2009).   The elevation of natriuretic peptides with aging has been previously 
reported in several studies (Redfi eld et al. 2002, Luchner et al. 2000, Sayama et al. 
1999), which may also explain the higher NT-proANP levels found in AD patients. 
(Buerger et al. 2009). Furthermore, blood pressure levels with a known elevating 
effect on natriuretic peptide concentrations were signifi cantly higher in AD patients 
than in the controls (Buerger et al. 2009). 
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The association of traditional cardiovascular risk factors with memory illnesses 
changes with age (Kerola, Kettunen and Nieminen 2011). The results of the present 
study show similar results, as the connection between BNP and memory illness 
was lost with aging. The impact of BNP on memory illness alters with aging either 
as an indicator in a cross-sectional setting or as a predictor for individuals without 
diagnosed memory illness. Amongst subjects younger than 79 years, BNP and 
memory illness had signifi cant association. In the oldest age group (83–96 years 
of age), this trend was reversed. In the oldest segment, higher BNP levels were 
connected with a lower prevalence of memory illnesses. This age-related change 
in the association between BNP and memory illness seemed to be explained by 
the elevation of BNP amongst individuals with no diagnosed memory illness. 
This fi nding is in concordance with earlier studies on BNP and aging, whereas 
in the present study the BNP levels amongst the patients with a memory illness 
did not increase with aging. Possible explanations for the elevation of natriuretic 
peptides with aging have been suggested. Morbidities such as heart failure and 
renal dysfunction increase the levels of natriuretic peptides (Vuolteenaho et al. 
2005). These conditions have been suggested as the reason for the elevation in 
natriuretic peptides amongst older individuals (Luchner et al. 2000, Sayama et 
al. 1999). The fact that comorbidity does not completely explain the increase of 
BNP levels with age supports the involvement of mechanism not yet recognised 
(Redfi eld et al. 2002). The results of the present study suggest that, in addition to 
defi ned factors, there are also other mechanisms leading to cognitive decline that 
also reduce the levels of BNP.  
The predictive value of natriuretic peptides on future cognitive decline has been 
addressed in only a few prospective studies. In an earlier investigation with the 
same study population as the present study, BNP had an independent predictive 
capacity on future memory illness (Kerola et al. 2010). In the previous study with 
the same population, traditional cardiovascular risk factors were taken into account 
but division into age-groups was not performed (Kerola et al. 2010). In one study 
(n=134), it was found that NT-proANP predicted the conversion of mild cognitive 
impairment into AD (Buerger et al. 2011) in persons below the age of 72 years. 
However, in patients older than 72, the predictive capacity of NT-proANP on 
progression of mild cognitive impairment to AD was no longer present, which is 
in line with the fi nding of the present study. The present analysis revealed that the 
signifi cant predictive power of BNP on memory illness was driven by the youngest 
age-group, 75–78 years, while the association was absent in older groups.  
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6.3.3 BNP AND SEVERITY OF MEMORY ILLNESS 
In the present study population, the levels of BNP were higher amongst people 
with mild memory illness than in the cognitively intact group, as was expected 
based on previous studies (Buerger et al. 2009, Gunstad et al. 2006, Kondziella 
et al. 2009, Buerger et al. 2011, Kerola et al. 2010). One previous investigation 
demonstrated an association between natriuretic peptides and the conversion of 
mild cognitive impairment (MCI) to AD in patients aged below 72, but not amongst 
older individuals (Buerger et al. 2011). However, it is noteworthy that MCI indicates 
a risk-state for cognitive decline, but not all individuals with MCI necessarily develop 
a memory illness in the future. The link between the progression of a diagnosed 
memory illness and natriuretic peptides has not been studied before. In our study, 
the levels of BNP decreased with the progression of memory illness, and individuals 
with more severe forms of memory illness had lower levels of BNP when compared 
to those with mild memory illness. Surprisingly, in patients with severe memory 
illness, the levels of BNP were numerically even lower, albeit without statistical 
signifi cance, than in participants without known memoriy illness. In a recent Dutch 
study, the prevalence of severe cognitive impairment amongst heart failure patients, 
its relationship with heart failure severity, its effects on morbidity and mortality, and 
the relationship between changes in heart failure severity and cognitive function 
were investigated. The main fi nding was that severe cognitive impairment was 
frequent amongst heart failure patients but that severe cognitive impairment was 
not related to NT-proBNP levels (Huijts et al. 2013). This fi nding is in concordance 
with our observation when it comes to the relationship between severe cognitive 
impairment and natriuretic peptides, but the results are confl icting with regard 
to heart failure as – since in our population, a history of heart failure was most 
prevalent in those with mild or moderate memory illness.  
 The reasons for the inverse U-shaped association between BNP and the 
progression of memory illness can be speculated. This phenomenon may be at least 
partly explained by changes in blood–pressure-related reasons, though mechanisms 
not yet understood are also possible. In the present study, the individuals included 
in the groups with any level of memory illness had signifi cantly lower systolic and 
diastolic blood pressure in comparison to their counterparts without known memory 
illness.  Arterial hypertension and other conditions related to high blood pressure 
have been found to elevate levels of BNP (Vuolteenaho et al.). This may partly 
explain our fi nding that the association between BNP and memory illness is lost 
with the progression of the disease. Our observation that individuals with memory 
illness had lower blood pressure than their counterparts without known memory 
illness is in agreement with earlier studies. In an older population, low diastolic 
blood pressure is related to an increased risk of developing a memory illness (Qiu 
et al. 2005), and the presence of memory illness has been associated with low blood 
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pressure (Molander et al. 2010). It has been reported that blood pressure begins to 
decline over approximately 3 years before the dementia syndrome becomes clinically 
evident (Qiu et al. 2009).  
Dehydration may lower the levels of BNP amongst individuals with progressed 
memory illness. Dehydration decreases the fi lling pressures and stretch of the left 
ventricle, which in turn attenuates the secretion of natriuretic peptides (Vuolteenaho 
et al. 2005). Older people often have an impaired ability to sense thirst (Waldreus 
et al. 2010), and chronic dehydration is common amongst the elderly, especially 
amongst cognitively impaired individuals (Morley 2002). In a Dutch study, causes 
of death amongst people suffering from the fi nal phase of memory illness (n=890) 
were investigated. The main fi nding was that cachexia and dehydration were the 
most common immediate cause of death in 35.2% of all deaths occurred, followed 
by cardio-vascular disorders (20.9%) and acute pulmonary diseases (20.1%) 
(Koopmans et al. 2007). In our study population, data on possible dehydration is 
unavailable. Therefore, the role of dehydration in lowering levels of BNP amongst 
groups with progressed memory illness can only be speculated on the basis of 
previous studies. 
There is also some controversy with regard to our fi ndings. BNP is excreted 
through the kidneys, and renal dysfunction is known to elevate the levels of 
natriuretic peptides (Vuolteenaho et al. 2005). Participants with a memory illness 
had lower creatinine clearance than participants with no diagnosed memory illness. 
It is possible that dehydration, as related to memory illness, may explain, at least 
partly, the lowered creatinine clearance. In addition, creatinine clearance is known 
to decrease with aging even without diagnosed renal disease (Muntner 2009, Sun 
et al. 2009). In the present study, participants with memory illness were older 
than the subjects without known memory illness, which may, for its part, explain 
the lowered creatinine clearance in those with a diagnosed memory illness. As 
lowered creatinine clearance should increase the levels of BNP, the role of creatinine 
clearance in our fi nding can be questioned. 
We knew, on the basis of earlier results, that the association between BNP and 
memory illness is lost with aging. Therefore, we wanted to further divide the severity 
groups of memory illness into age tertiles and test whether this association was still 
absent in various stages of memory illness. When the study population was divided 
into age tertiles, the inverse U-shaped association between BNP and memory illness 
stage was lost in the oldest tertile, where the highest level of BNP was found in the 
group without diagnosed memory illness. This age dependency is in accordance 
with the other fi ndings of this study, as the association between memory illness and 
BNP was shown to be age-dependent. In addition, in line with earlier studies, the 
presence and stage of memory illness were connected to higher age, short education, 
low cholesterol and renal dysfunction (Mielke et al. 2005, Evans et al. 1989, Gureje 
et al. 2011, Valenzuela et al. 2011, Lobo et al. 2011, Sasaki et al. 2011).  
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6.4 METHODOLOGICAL ISSUES 
This study is a prospective population-based cohort study, with the exception of 
sub-study III which had a clearly cross-sectional setting. The outcome measure of 
a prospective study must be well defi ned and accurately measurable (Hlatky et al. 
2009).  Death as an outcome measure fulfi ls these preconditions. The case is more 
complex with memory illness. In most cases, a diagnosis of memory illness in older 
individuals can be reliably established but, at times, there are uncertainties in the 
matter of diagnosis. For example, somatic and also psychiatric conditions may 
negatively infl uence cognition in older people. The demanding task of diagnosing 
memory illness was dealt with by employing an experienced neurologist and 
geriatrician (R.S.) and DSM-IV criteria for evaluating and diagnosing memory 
illnesses.   
 The evaluation of a new risk marker starts with a proper study design and a 
representative at-risk population. Cohort studies in which participants are followed 
up over time and outcomes ascertained prospectively provide the best information 
regarding prognosis (Hlatky et al. 2009).  The design and reporting of risk marker 
assessment studies should conform to generally accepted standards of clinical 
research, such as the recent Strengthening the Reporting of Observational Studies 
in Epidemiology guidelines (The STROBE statement) (Simera et al. 2010, von Elm 
et al. 2007). The original articles included in the present study were prepared using 
the principles outlined in the STROBE statement. The study population represented 
a random sample of older people aged 75 years and over, which is a clinically 
relevant age group when studying the epidemiology of memory illness. The non-
participation rate was 14% (including those who refused to participate, died or could 
not be reached), which is considered low, yielding a good generalisability amongst 
Finnish older people. The size of the fi nal study population is comparable to or 
even larger than many previous studies on the fi eld (Buerger et al. 2009, Gunstad 
et al. 2006, Strandberg et al. 2009, Buerger et al. 2011, van den Broek et al. 2011). 
The number of outcome events available for analysis can also be increased by 
longer follow-up. The risk of outcome events is estimated on the basis of the number 
of outcome events over a certain interval of time and conventionally summarised 
either with a survival curve or by reporting the proportion of events over a fi xed 
time interval of interest. For a short fi xed follow-up time, logistic regression can 
be used for risk evaluation. A Cox proportional hazards model is preferable for a 
longer time of follow-up and when there is variation between the follow-up times 
of individuals. Using a multivariable model allows demographic factors and other 
risk markers to be taken into account when assessing the independent role of a 
single risk factor (Hlatky et al. 2009). In sub-studies I and IV, a Cox proportional 
hazards model was used to estimate the risk of mortality. The follow-up period 
lasted up to 96 months. In sub-study II, the follow-up time was a fi xed fi ve years, 
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at which point a pre-planned control visit was scheduled, and a logistic regression 
model was used to investigate the prognostic capacity of BNP on memory illness. 
A cross-sectional setting was used in sub-study III when the association of BNP 
with the severity of memory illness was investigated.  
Conventionally, the association between outcome and a suggested risk marker 
must be statistically signifi cant before any usability of the risk marker can be 
proposed. This requires a suffi cient number of outcomes during follow-up. In a 
nutshell, this means that the statistical power of risk assessment depends on the 
number of outcome events available for analysis and not on the number of subjects 
studied or the length of follow-up (Hlatky et al. 2009). In the present study, both 
the all-cause and the total mortality rate were high, most likely due to demographic 
factors (i.e. age) and morbidity. The number of new cases of conditions causing 
memory illness during the fi ve-year follow-up was also relatively high. The numbers 
of outcome are comparable with earlier studies, and often even clearly superior 
(Buerger et al. 2009, Gunstad et al. 2006, Strandberg et al. 2009, van den Broek 
et al. 2011), which strengthens the reliability of the results. 
A requirement for a novel risk marker is also that it improves risk prediction 
beyond traditionally used risk markers. This means that a new risk factor should 
be tested in a multivariable model together with established risk markers before 
the additive value of a new marker can be estimated (Hlatky et al. 2009). All the 
sub-studies included in this dissertation addressed this issue by using multivariable 
models. 
 This study also has several limitations. In our study population, the prevalence 
of heart failure (24.6%) and other cardiovascular conditions was markedly higher 
than in most of the studies focusing on the epidemiology of heart failure (Redfi eld et 
al. 2003, Strandberg and Tilvis 2000). The diagnosis of heart failure was obtained 
from the medical records, which may have caused a degree of over-diagnosis. 
Nevertheless, Eastern Finland is known for an exceptionally high cardiovascular 
disease burden (Pyörälä et al. 1985).  In the analysis between the various memory 
illnesses, the number of participants with diagnosed VaD and DLB was low, which 
reduced the ability to detect signifi cant differences between the memory illness 
groups (sub-study II). However, the absolute values for natriuretic peptides were 
relatively close to each other, suggesting that potential differences would not be 
clinically important. Moreover, the number of participants in the subgroups divided 
by the severity of memory illness was low, which decreased the ability to detect 
signifi cant differences in blood BNP levels between the groups (sub-study III). A 
minor independent connection between depressive symptoms and mortality as 
well as cardiovascular mortality cannot be excluded, due to the size of the study 
population (sub-study IV). The prevalence of depressive symptoms was high, which 
may be due to high cardiovascular and other morbidity in the study population and 
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also due to the Zung SDS score cut-off point being set to 40. The ZDS score cut-off 
point of 40 for elevated depressive symptoms has been used in the literature and, in 
this sense, our cut-off point was justifi ed. The extrapolation of the results to other 
age groups or other ethnic groups besides Caucasians should be done with caution. 
The strengths of our study include the population-based approach and extensive 
characterisation of the study population. 
6.5 FUTURE PERSPECTIVES  
According to the present knowledge, natriuretic peptides as markers of cardiovascular 
stress have shown predictive value for memory illnesses and mortality in the elderly. 
However, the prognostic value of natriuretic peptides for individual subjects has not 
been studied. The threshold levels of natriuretic peptides for recognising individuals 
at an elevated risk of mortality or developing a memory illness are not known and, 
therefore, natriuretic peptides have not been recommended for evaluating the risk 
in asymptomatic adults. Several factors infl uence the levels of natriuretic peptides, 
and these factors tend to accumulate in older people. Some of these factors are 
demographic, such as age and sex, and cannot be modifi ed; the related variation 
in natriuretic peptides should be taken into account in prognostics. However, there 
are several known modifi able factors that have an effect on the haemodynamic 
load and thus on the levels of natriuretic peptides in an older population. The key 
question is: what is/are the factor(s) affecting the levels of natriuretic peptides 
in an individual that is/are clinically relevant in predicting cognitive decline and 
mortality? A challenge for the the future shall be to develop an easy-to-use clinical 
assessment tool to identify patients at an increased risk, and the levels of natriuretic 
peptides could be included in such a risk evaluation tool that a physician would be 
able to use in daily practice.  
Changes in blood pressure combined with the levels of natriuretic peptides over 
time provide one interesting approach to improve the prognosis, as a decline in 
blood pressure has been reported to start years before the diagnosis of memory 
illness. In the absence of curative treatment, it would be benefi cial if the onset of 
memory illness could be postponed even by one year. An early diagnosis of memory 
illness enables the initiation of early treatment, which may slow down cognitive 
decline. However, this thesis showed that the association between levels of BNP 
and memory illness is age-dependent, which complicates the utility of natriuretic 
peptides as prognostic tools for future cognitive decline in the elderly. Furthermore, 
levels of BNP decline with the progression of memory illness, being at their highest 
level in the early phase of the disease, which indicates changes in the haemodynamic 
load as the disease progresses. On the basis of our cross-sectional sub-study, no 
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causality can be indicated between haemodynamic load and the severity of memory 
illness. It would be interesting to investigate whether infl uencing this change in 
haemodynamic load could affect the rate of disease progression. The possibility to 
delay the progression of a diagnosed memory illness by means of an intervention 
aimed at modifi able factors would bring enormous economic savings due to the 
decreased need for care – not to mention the reduction in human suffering if the 
disease progression can be delayed. 
This study showed that an increased haemodynamic load increases the risk of 
death, regardless of other risk factors in an elderly population. Moderately attenuated 
MMSE score also had predictive value for total mortality. Our results support the 
use of MMSE score together with cardiovascular risk factors in screening older 
individuals at an elevated risk of mortality. Depressive symptoms, for their part, 
had no independent prognostic value for mortality but were linked to cardiovascular 
morbidity, which is in concordance with earlier literature of the subject. The present 
results do not suggest the use of depressive symptoms in screening patients at a high 
mortality risk; instead, the fi ndings promote paying particular attention to somatic 
conditions in older people complaining of depressive symptoms. However, more 
studies are needed to investigate effect of the interplay between haemodynamic load 
and depressive symptoms on mortality in older people, since studies conducted on 
general older populations are few. Again, multimorbidity in older people complicates 
screening and a systematic guideline cannot be given, but risk assessment has to 
be performed individually until further information is available.  
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7 CONCLUSIONS 
The following conclusions can be made based on this study: 
1. BNP – a marker of cardiovascular stress – and a moderately attenuated MMSE 
score (18-23) are both independent predictors of total mortality. An MMSE score 
of 18–23 does not independently predict cardiovascular mortality, whereas BNP 
remains a strong predictor of cardiovascular mortality. 
2. The previously found link between a high BNP concentration and cognitive 
dysfunction is age-dependent. In the oldest segment of the general population, 
elevated BNP levels are associated with a lower prevalence of memory illnesses. 
Furthermore, BNP was superior in its connection to memory illness when compared 
to ANP or NT-ANP. 
3. The previously reported elevation of natriuretic peptides amongst individuals 
with a diagnosed memory illness occurs only in individuals with milder stages of 
the illness. Moderate and severe stages of memory illness were most common in 
the oldest segment of the study population, and the age-dependency of BNP and 
memory illness is likely to partly explain this fi nding. In addition, comorbidities and 
behavioural changes connected to progressed memory illness are other probable 
causes of the decrease in BNP levels that occurs in a more advanced memory illness. 
 
4. In an elderly general population the prognostic capacity of depressive symptoms 
is closely linked to cardiovascular morbidity and has no independent power. On the 
other hand, BNP remains a strong predictor of both all-cause and cardiovascular 
mortality regardless of depressive symptoms status. 
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